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1 PREFACE
Inflammatory bowel disease (IBD) includes the two disease entities ulcerative colitis (UC) 
and Crohn’s disease (CD). These two chronic relapsing diseases are closely related and partly 
overlapping in terms of clinical picture, management and putative etiology. The diseases 
inflict disabling symptoms like diarrhea, abdominal pain, and fever and require advanced 
medication and often major surgery (Baumgart and Sandborn, 2007). Untreated the diseases 
confer increased risk of colonic cancer (Baumgart and Sandborn, 2007).
Historically IBD has been a disease of industrialized parts of the world with reported 
incidents rates in Europe and North America for both entities ranging from 3 to 15 (10 000-1)
(Loftus, Jr., 2004). After steady increase throughout the last century the adult incident rates 
have now stabilized in high incident areas while rates in previously low incident areas like 
Africa, Asia, and Latin America are increasing (Loftus, Jr., 2004). As chronic disorders the
IBD burden is better described by the prevalence, which indicates that 1.4 million persons in 
the United States and 2.2 million persons in Europe suffers from IBD (Loftus, Jr., 2004). The 
direct costs per patient per year in the United States is estimated to be nearly 10 000 USD  and
higher for children than for adults (Kappelman et al., 2008). In addition come the hard-to-
analyze indirect costs in terms of reduced employment and productivity (Park and Bass, 
2010).
IBD has long been considered to occur as a response to environmental factors in 
genetically susceptible persons (Baumgart and Carding, 2007). The last decade has identified
susceptibility genes for IBD, many of which have in common that they play a role in the 
human organism’s handling of intestinal microbes. The “hygiene hypothesis” suggests that 
increased IBD incidence rates in areas adapting a western world standard of living, included 
improved hygiene, is caused by alteration in the composition of the intestinal microbiota
(Baumgart and Carding, 2007; Koloski et al., 2008). However, despite intense research and 
great progress the pathogenic mechanisms underlying IBD remain enigmatic.
If able to identify and solve only one tiny piece in the giant puzzle of IBD
pathogenesis, one could potentially move closer to prevention of the disease or to the 
invention of new therapies, which would reduce the disease burden both for individuals and 
society.
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2 INTRODUCTION
2.1 IBD – clinical aspects
UC’s is a relapsing chronic inflammation. The gut inflammation is restricted to the colon,
where it starts distally and spreads continuously in the proximal direction, causing superficial 
mucosal ulcerations. The affected area at diagnosis generally corresponds to disease severity.
Patients typically experience bloody diarrhea, which may include mucus and pus, often 
present at night and followed by abdominal cramps. Severe cases may present with systemic 
toxicity such as fever, tachycardia, anemia and colonic dilation. After medical induction 
therapy the prevalence of patients in remission is approximately 50%, but 9 out of 10 patients 
experience relapses. Total colectomy is curative and 10 years after diagnosis 1 out of 4 
patients are colectomized.
CD is also a chronic and relapsing disease but distinguishes itself from UC in some 
aspects.  CD causes transmural inflammation that may affect any part of the gastrointestinal 
tract. Lesions are generally discontinuous (“skipped lesions”) and can be numerous. Half the 
patients present with lesions in the terminal ileum while approximately 1 out of 4 patients
present with colonic lesions and 1 out of 4 with ileocolonic lesions. The transmural 
inflammation facilitates strictures and fistulas and the clinical presentation relates to the 
anatomical localization and type of complicating pathology and may change over time. The 
typical presentation is diarrhea, abdominal pain, fever, and signs of bowel obstruction. The 
first year after medical induction therapy more than half the patients are in remission, but only 
1 out of 10 stays in remission for several years while the rest have a chronic active or chronic 
intermittent course. Twenty years after diagnosis most CD patients will have undergone 
surgery due to strictures or fistulas.  
In CD, but not in UC, the life expectancy is slightly reduced compared with the 
general population. Both UC and CD confer increased risks for colonic cancer, most 
frequently adenocarcinoma. The risk of cancer seems to be correlated to the length of the 
affected gut, and is less increased in patients that adhere and respond to anti-inflammatory 
therapy. 
After exclusion of other causes of enteritis the diagnosis of both UC and CD are 
clinical, based on history and physical examination, supplemented by laboratory tests and
confirmed by histological assessments. Over the last decades endoscopy has become the key 
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examination, both for close-up visual evaluation of mucosal appearance and disease 
distribution and to obtain tissue specimens for histopathological evaluation. In addition, 
radiological imaging is important for assessment of the extra-colonic distribution of CD.  
An overview of the clinical aspects of UC and CD is presented by Baumgart &
Sandborn (Baumgart and Sandborn, 2007).
2.1.1 Pediatric vs. adult onset IBD
IBD may debut at any age. Worldwide, 10-25 % of all IBD patients are diagnosed before 18 
years of age (Griffiths, 2004; Nieuwenhuis and Escher, 2008). Even though the total 
incidence  rates of IBD has stabilized in industrialized countries (Loftus, Jr., 2004), there are 
several recent reports from industrialized countries pointing to an increased incidence of 
pediatric onset IBD over the last 20 years (Perminow et al., 2009; Benchimol et al., 2009; 
Turunen et al., 2006; Orel et al., 2009; Malaty et al., 2010).
Though the nature of the clinical presentation of pediatric IBD is the same as in adult-
onset disease some differences exist (Sauer and Kugathasan, 2009; Griffiths, 2004): While 
UC and CD occur in similar rates in adults, there is a preponderance of CD in pediatric 
patients. Pediatric CD also occurs more frequently in boys than in girls while a gender 
difference is not observed in adults. Moreover, pediatric IBD differs from adult disease with 
respect to disease location. The most frequent disease location in adult CD is the terminal 
ileum. Isolated ileitis is less frequent in pediatric patients as adolescent patients more often 
present with a pan-enteric disease and the young children more often present with isolated 
colonic CD. Pediatric-onset UC more often presents with pan-colitis and a more severe 
disease phenotype at diagnosis. Ten years after diagnosis twice as many pediatric UC children 
have undergone surgery compared with adult-onset UC patients.
Pediatric IBD patients naturally have a shorter exposure time to environmental 
pathogenic factors than adults, and thus it has been proposed that genetics play a more 
important role in the disease development in children. Researchers argue that pediatric-onset 
disease should be regarded as a separate entity within IBD, and further research on pediatric 
IBD has been warranted (Kugathasan and Cohen, 2008).
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2.2 The intestinal microbiota
The lumen of the mammalian gastrointestinal tract harbors a vast amount of microbes. It is 
estimated that the microbial concentration in the colon is 1011 cells/ml, which implies that the 
total number of microbial cells in the human gut is in the range of 1014 (Ley et al., 2006).
This microbial community, often termed commensal or mutualistic, outnumbers the cells of 
the human organism by an order of magnitude. New DNA sequencing technology has enabled 
scientists to estimate the intestinal microbiota’s collective genome (a.k.a. metagenome or 
microbiome) to contain more than 3x106 different genes, which is 150 times the number of 
human genes (Qin et al., 2010). Considering this metagenome’s proximity to the human 
genome a modern view is to look at man as a super-organism whose genetic information is 
provided both by the human cells and by the microbial metagenome (Gill et al., 2006; 
Peterson et al., 2008). Assessments of the intestinal microbiota were for many years based on
bacterial cultivation. However, only a fraction of the intestinal microbiota can be cultured ex 
vivo. Sequencing and bioinformatic studies of the highly conserved 16S rRNA gene (See also
section 5.5.2) present in all bacteria have tremendously improved our insight into the 
composition and the evolution of the intestinal microbiota (Peterson et al., 2008). Very
recently, deep sequencing technology of the metagenome has provided additional 
information to metagenomic studies (Qin et al., 2010; Nelson et al., 2010).
The intestinal microbiota consists of all three domains of life: Eukarya (i.e. fungi, 
parasites), Archaea and Bacteria. 99% of the gut metagenome is of bacterial origin, which 
consequently is the most studied (Qin et al., 2010). Of 55 divisions in the kingdom of Bacteria 
only seven are represented in the gut, a low number compared to other ecological habitats.
Two phyla, the Firmicutes and the Bacteriodetes, represent 98% of the 16S rRNA gene 
sequences in the healthy human gut (Ley et al., 2006). Within these phyla there are around 
102-103 different species, depending on the metagenomic definition of a species, and 104
phylotypes on strain level. This pattern with a shallow widespread fan-like phylogenetic tree 
is typical for an environment with extreme selection pressure (Ley et al., 2006). To be 
established as gut residents bacteria have to overcome lack of light, low oxygen tension,
limitations in substrates for energy production, rapid turnover of epithelial cells, the
mechanical propulsion of luminal contents, and the potential combat with the host immune 
system (Ley et al., 2006; Sonnenburg et al., 2004). Also, from an evolutionary point of view,
bacteria that provide benefits for the host will be selected. The microbiota provides an 
enzymatic machinery for digestion of plant saccharides, which complements the limited 
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glycosylhydrolase repertoire of the mammalian genome and allows increased energy 
utilization from a plant rich diet (Ley et al., 2008; Hooper et al., 2002). Microbial enzymes are 
also essential for synthesizing vitamin K and certain B vitamins (Hooper et al., 2002). The 
commensal microbiota occupy an ecological niche that could otherwise be exploited by 
pathogenic bacteria so they offer a colonization resistance to potential pathogens (Stecher and 
Hardt, 2008). The importance of the microbiota to stimulate the host immune system is 
presented in later sections.
Cultivation based studies have shown that newborns acquire their initial gut 
microbiota from the feces and vagina of their mothers at birth (Ley et al., 2006). The 
composition of the microbiota is chaotic the first year of life, but eventually stabilizes and 
shows little temporal variation in healthy adults (Rajilic-Stojanovic et al., 2009; Ley et al., 
2006; Peterson et al., 2008). Potential modifications of the microbiota are derived from 
environmental factors such as diet and antibiotic use (Maslowski and Mackay, 2011; Willing 
et al., 2011). Preliminary studies of intra-individual spatial variations in the composition of 
the microbiota along the healthy gut have revealed small differences (Peterson et al., 2008; 
Eckburg et al., 2005). However, there is a gradient in the magnitude of the microbial load 
along the gut with bacterial densities of 102 cells/ml in the proximal small intestines to 1011
cells/ml in the colon (Sartor, 2008). In summary, a healthy person’s microbial composition is 
fairly stable and determined by the microbes one is exposed to after birth as well as to yet
unidentified genetic factors (Spor et al., 2011).
Even though analyses of the microbial composition show intra-individual stability
there are great inter-individual diversities (Peterson et al., 2008; Eckburg et al., 2005).
Phylogenetic microarray and metagenomic catalogue studies have reported that less than 20% 
of the phylotypes at the species levels are uniformly present in unrelated persons (Rajilic-
Stojanovic et al., 2009; Qin et al., 2010). It is believed that humans carry a core microbiota of 
essential species but that there is a vast inter-individual species-specific diversity outside of 
this core microbiota.
Recently, alterations in the composition of the intestinal microbiota have been shown 
to be associated with obesity, a finding that demonstrate the significance of the microbial 
community for human health (Turnbaugh et al., 2009). Furthermore, experimental animal 
models for several autoimmune diseases like type 1 diabetes mellitus, multiple sclerosis and 
ankylosing enthosopathy are dependent on microbial stimuli (Wen et al., 2008; Ochoa-
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Reparaz et al., 2010; Chervonsky, 2010). Perturbations of the intestinal microbiota associated 
with IBD are discussed in section 2.4.
2.3 The intestinal mucosal immune system
All organisms have developed defense systems to protect themselves from foreign matter like 
microbes and viruses. Mammals have evolved a highly complex immune system; which, for 
didactic reasons is divided into two systems: the innate and the adaptive immune systems. The 
two systems overlap and interrelate extensively. An extensive and general overview of the 
innate and adaptive immune systems can be found in text books (Janeway, 2005). A minute 
introduction of the two systems’ key characteristics exemplified by the defense against 
microbes in the gut is presented in this chapter.  It further presents an overview of mucosal 
immunity and is followed by sections on elements of mucosal immunity related to the aims of 
this thesis.
The innate immune system refers to the antigen non-specific defense against a foreign 
threat. On front line, the defense system involves mechanical barriers like stratified 
epithelium of the esophagus, mucus lining the epithelial cells, which again are sealed together 
by tight junctions and constantly shed and renewed, and the propulsion of the luminal 
contents by peristalsis. Mammals also have chemical barriers in the gastrointestinal tract 
consisting of a low pH in gastric juices, non-specific enzymatic protein digestion, and 
secretion of anti-microbial peptides (AMP) from epithelial cells. Resident commensal bacteria 
occupying the ecological niche in the gut may also be regarded as part of the super-
organism’s innate defense system as they provide a colonization resistance to pathogenic 
microbes (Stecher and Hardt, 2008).
Leukocytes of hematopoietic origin are the central cell types (Figure 1) to combat 
microbes that overcome the physical and chemical barriers. Macrophages and neutrophils 
reside in or are rapidly recruited to the lamina propria, respectively. They have the capability 
to neutralize intruders by phagocytosis and subsequent intracellular destruction, or by 
degranulation of preformed granules containing toxic substances. Notably, the toxicity of 
degranulation works unspecifically and also causes harm to the host tissue (Mosser and 
Edwards, 2008). Dendritic cells (DC) are also phagocytic and are important for processing of 
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microbial molecules and presenting them for lymphocytes. Activated DCs migrate to
lymphoid tissue and bridge the innate and adaptive immune system.
Figure 1. Overview of innate and adaptive hematopoietic immune cells. The innate immune 
response functions as the first line of defense against infection. In addition to tissue-specific cells (e.g. 
epithelial cells), the innate immune cells consist of hematopoietic cells including granulocytes
(basophils, eosinophils and neutrophils), mast cells, macrophages, dendritic cells, and natural killer 
cells. The adaptive immune response is slower to develop, but is antigen specific and has memory. It 
consists of B cells and CD4+ and CD8+ T lymphocytes. Natural killer T cells and T cells are 
cytotoxic lymphocytes that straddle the interface of innate and adaptive immunity.
Reprinted by permission from Nature Publishing group, Nature Reviews Cancer (Dranoff) © 2004. The 
figure legend has been modified.
The ability to discriminate foreign material from the organism’s own is essential to the 
immune system. For innate immune cells this is provided by a set of pattern recognition
receptors (PRRs). PRRs are germ-line encoded and highly conserved. They are expressed by 
leukocytes and also by non-hematopoietic cells like epithelial cells. The transmembrane Toll-
like receptors (TLR) and the cytosolic nucleotide-binding oligomerization domains (NOD) 
are two of the most studied classes of PRRs. The ligands for PRRs are conserved peptides
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(e.g. flagellin), glycoproteins (e.g. peptidoglycan), lipopolysaccharide (LPS), or nucleic acid 
structures (e.g. unmethylated CpG, double-stranded RNA) that are common to a wide range 
of microbes, but not expressed by the mammalian cells. These ligands are collectively termed 
microbe-associated molecular patterns (MAMP). Engagements of PRRs by MAMPs induce
signaling cascades facilitating transcription of pro-inflammatory molecules. In summary, the 
innate immune system discriminates between self and non-self and relies on germ line-
encoded molecules that are partially preformed and rapidly mobilized. The innate immune 
response is an immediate and unspecific reaction that occurs in minutes and hours after an 
intruder has been recognized.
The adaptive immune response starts if an infection is not cleared by the innate 
immune response within hours. The adaptive response is mediated by B and T lymphocytes. 
B cells have the ability to differentiate into plasma cells which produce immunoglobulins (Ig)
and are the main effectors of humoral immunity. T cells mediate cellular immunity through 
killing of infected cells by the subset cytotoxic T cells (CD8+), or through CD4+ T cell 
subsets’ activation or modulation of B cells and cytotoxic T cells.
Essential in adaptive immunity are the antigen-specific response and the concepts of 
clonality and immunological memory. Each B or T lymphocyte has a single type of receptor
with unique specificity, i.e. B cell receptor (BCR) or T cell receptor (TCR). High affinity 
interaction between a lymphocyte receptor and an antigen recognized as foreign leads to 
activation of the actual lymphocyte. The vast numbers of T and B cells present in the body 
collectively provide a near infinite number of BCR and TCR specificities. All cells derived 
from an activated lymphocyte will bear the identical receptor specificity as this lymphocyte.
Igs have specificity identical with the BCR and are accordingly also of clonal origin. The 
antigen, most often of protein nature, has to be processed and presented as fragmented 
peptides to the TCR on major histocompatibility complex (MHC) II molecules, which are 
present on antigen-presenting cells (APC) like DCs, macrophages and B cells, or on MHC I 
molecules present on all nucleated cells. A lymphocyte that is activated by specific high-
affinity binding to an antigen-MHC II complex will proliferate. This clonal expansion is 
important for the power of the immune response. The primary adaptive immune response is a
slow reaction and takes hours and days to be raised. After the primary immune response has 
resolved most of the antigen-specific activated lymphocytes undergo apoptosis. However, a 
significant number of cells persist in a dormant state. These memory cells ensures a more 
rapid and effective response the second time the immune system encounter the same antigen.
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Innate immune responses take place in all tissues. Gut mucosal adaptive immune 
responses are induced in specialized lymphoid tissue called gut-associated lymphoid tissue
(GALT). GALT consists of Peyer’s patches (PP) in the small intestines and isolated lymphoid 
follicles (ILFs) located throughout the gut mucosa. Antigens are sampled at these inductive 
sites and presented to lymphocytes, which subsequently drain to the mesenteric lymph nodes
(MLN) and then to blood via the thoracic duct. Educated lymphocytes home to the lamina 
propria, the effector site of mucosal adaptive immunity, where they exert their effects.
2.3.1 Overview of mucosal immune homeostasis
In the gut, the cumulative area of the mucosal membrane is several hundred square meters
(Brandtzaeg, 2009). A single layer of columnar epithelial cells divides the interior from the 
luminal exterior, which is occupied by 1014 microbes and a vast load of foreign dietary 
materials. Consequently the mucosal membrane is a vulnerable surface, and the ability to 
maintain homeostasis with tolerance to commensal microbes and concurrent responsiveness 
to pathogens and intruders is of paramount importance. This ability can be viewed as a
hierarchy of three immunological barriers (Hooper and Macpherson, 2010). The first layer 
limits the physical contact between the intestinal microbes and the epithelial cells. The second 
layer provides rapid detection and elimination of microbes that manage to penetrate the 
epithelial barrier. Figure 2 gives an anatomical overview of the first two layers of the 
intestinal immunological barriers. The third layer consists of immune responses that minimize 
the exposure of microbes to the systemic immune system.
Three components contribute to prevent direct contact between microbes and 
the epithelium: mucus, AMPs, and secretory immunoglobulins (SIg). Specialized intestinal 
epithelial cells called Goblet cells localized in the mucosal crypts constitutively secrete 
mucin, which is a highly glycosylated protein (Johansson et al., 2008). The mucin forms a 
protective mucus layer up to 150 µm thick on the apical side of the epithelial cells. The mucus 
layer is divided into two layers were the inner and more densely stratified layer is devoid of 
bacteria (Johansson et al., 2008). Experimental deletion of the mucin production in mice leads 
to bacterial penetration and spontaneous colitis (Johansson et al., 2008; Van der et al., 2006).
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Figure 2. Microanatomy of the intestinal immune system. A single layer of intestinal epithelial cells
(IECs) separates the intestinal lumen from the underlying lamina propria. The IECs lining the lumen 
are bathed in nutrients, commensal bacteria, IgA and goblet cell-produced mucus. Epithelial stem cells 
proliferate and give rise to daughter cells with the potential to proliferate. These IECs then differentiate 
into villous or crypt enterocytes, which absorb nutrients (small intestine) and water (colon). In addition 
to differentiated enterocytes and goblet cells, progenitor IECs differentiate into Paneth cells at the 
base of the small intestinal crypts. Beneath the IECs, the lamina propria is made up of stromal cells
(myofibroblasts), B cells (especially IgA-producing plasma cells), T cells, macrophages and dendritic 
cells. Certain subsets of T cells and dendritic cells localize between the IECs. The small intestine has 
regions of specialized epithelium termed follicle-associated epithelium and microfold (M) cells that 
overlie the Peyer's patches and sample antigens from the intestinal lumen. IEL, intraepithelial 
lymphocyte.
Reprinted by permission from Nature Publishing Group. Nature Reviews Immunology (Abreu) © 2010. 
The figure legend has been modified
AMPs are small peptides of several families including 			
	
, and Ang4. They exert strong antimicrobial activity, most  
frequently by enzymatic disruption of the bacterial cell wall or cell membrane (Hooper and 
Macpherson, 2010; Dann and Eckmann, 2007). Some of the AMPs are secreted constitutively 
from a wide range of cells types (Dann and Eckmann, 2007), while others are selectively 
expressed by specialized epithelial cells like Paneth cells in the small intestine and are
induced by microbes (Brandl et al., 2008; Vaishnava et al., 2008; Nair et al., 2008) or 
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MAMPs (Cash et al., 2006) in a PRR-dependent manner (Vaishnava et al., 2008; Brandl et al., 
2007; Kobayashi et al., 2005). AMPs are not found in the gut lumen but retained in the apical 
mucus layer, thus setting up an AMP diffusion gradient which microbes have to travel against 
to reach the epithelial surface (Meyer-Hoffert et al., 2008). Disrupted production of certain 
classes of AMPs is associated with Crohn’s disease (Wehkamp et al., 2008).
SIgs, as the third contributing component to keep microbes off the epithelial surface 
are thoroughly discussed in the 2.3.3.n sections.
The second hierarchical layer providing mucosal homesteostasis is the rapid detection
and elimination of microbes that have penetrated the epithelial barrier (Hooper and 
Macpherson, 2010). This is foremost facilitated by resident macrophages, which are discussed 
in section 2.3.4. Adaptive immunity also comes into play at this level. Microbial antigens are 
engulfed and digested by DCs and presented to CD4+ T cells. DCs reside beneath the 
intestinal epithelium and are especially abundant beneath the follicle-associated epithelium of 
PPs. The follicle-associated epithelium lacks coverage of protective mucus and harbors 
scattered microfold (M) cells, which efficiently transcytose luminal products across the 
epithelium (Brandtzaeg, 2009). Mucosal DCs are of different functional subsets. Some DC 
subsets migrate constitutively to lymphoid tissue (i.e. PP, MLN) where they present their 
antigens to naïve CD4+ T cells and where also naïve B cells are present (Coombes and 
Powrie, 2008). These lymphocytes are then activated and imprinted with the gut-specific 
homing molecules integrin 47 and chemokine receptor CCR9, which make them - after 
circulation via lymph and blood - return to the gut lamina propria as antigen-specific 
activated lymphocytes (Brandtzaeg, 2009). Further details on the mucosal B cell activation is 
presented in section 2.3.3.1. Other DC subsets are non-migratory and present antigens to 
CD4+ T cells in the lamina propria (Coombes and Powrie, 2008). The outcome of the DCs’ 
antigen presentation and activation of T cells is dependent on conditioning of the DCs. In a 
homeostatic situation, the cytokine environment in the lamina propria is dominated by thymic 
stromal lymphopoietin (TSLP), 			 (TGF-), retinoic acid (RA), IL-
10, and prostaglandins produced by epithelial cells, stromal cells, macrophages and 
lymphocytes (Rescigno and Di, 2009; Coombes and Powrie, 2008). These cytokines condition
DCs to favor induction of the transcription factor Forkhead box P3 (Foxp3) in naïve CD4+
cells, which then become regulatory T cells (Tregs) and maintain specific tolerance to the 
commensal microbes (See section 2.3.5 for further details). On the other hand, if a microbial 
product is perceived as a pathogen, the cytokine environment turns pro-inflammatory and 
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DCs will activate pro-inflammatory transcriptional programs in CD4+ T cells, which become 
pro-inflammatory Th1 or Th17 cells (Coombes and Powrie, 2008).
An additional mechanism that contributes to this second hierarchical layer is the 
antigen excretion provided by secretory immunoglobulins (SIgs) and the polymeric 
immunoglobulin receptor (pIgR) (Strugnell and Wijburg, 2010). This mechanism is presented 
in detail in sections 2.3.3.2-3.
The third hierarchical layer of protection is a firewall between the mucosal and the 
systemic immunological compartments (Hooper and Macpherson, 2010). In healthy mice,
commensal microbes can be cultured from MLN of immune competent mice but not from 
blood or systemic organs (Macpherson and Uhr, 2004). Live commensal microbes travel with 
migratory DCs from the lamina propria to MLNs and enhance activation of commensal-
specific B and T lymphocytes, which are subsequently put into circulation and disseminated 
throughout the gut by homing mechanisms described above. The efficacy of the firewall 
depends on the competence of the first and second layer of protection. For instance, defective 
protection by IgA results in increased commensal specific serum IgG indicating systemic 
exposure to commensal microbes (Macpherson et al., 2000; Johansen et al., 1999; Sait et al., 
2007).
2.3.2 Intestinal epithelial cells as immune cells
As mentioned in previous sections, a single layer of columnar epithelial cells provides the 
barrier between the organism’s interior and exterior. The former is striving for sterility while
the latter is comprised of a vast microbial load. The epithelial cell membrane is impermeable 
to hydrophilic molecules that lack specific transporters while tight junction protein complexes 
seal off the paracellular route (Turner, 2009). For long, the epithelium was only 
acknowledged for its simple mechanical barrier function in addition to exchange of nutrients 
and water. In recent years the importance of the intestinal epithelial cells’ (IEC) contribution 
to the mucosal immune homeostasis has been recognized (Artis, 2008).
IECs are constantly renewed and originate from intestinal stem cells located near the 
crypt base (Scoville et al., 2008) (Figure 2). The IECs proliferate and differentiate in the 
crypts, migrate up, and eventually undergo apoptosis on the surface epithelium in an 
approximately five day long cycle (Abreu, 2010). Differentiated IEC to be mentioned for their 
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immune functions are: a) AMP-releasing Paneth cells in the lower parts of small intestine 
crypts; b) mucin-producing Goblet cells throughout the crypts; and c) M cells located in the 
subepithelial dome of Peyer’s patches and ILFs, which facilitate transepithelial transport of 
luminal antigens for education of mucosal adaptive immune cells. In addition, the generally
absorptive enterocytes have important innate immune functions. In steady state situation,
IECs are important producers of the cytokines TSLP, TGF-	prostaglandin E-2, and retinoic 
acid, which all are important for a tolerogenic and anti-inflammatory cytokine milieu in the 
lamina propria (Rescigno and Di, 2009; Shale and Ghosh, 2009). IEC also produce the two 
cytokines BAFF and APRIL which are considered to be important for immunoglobulin class 
switching to IgA (Cerutti and Rescigno, 2008). In contrast to these homeostatic features, IECs 
may contribute to mucosal inflammation by release of pro-inflammatory cytokines, 
chemokines and co-stimulatory factors for effector T cells (Baumgart and Carding, 2007).
IECs may express a wide array of PRRs and still remain tolerant to the commensal 
microbes in their immediate vicinity. Several models have been proposed to explain this 
paradox (Duerkop et al., 2009). In a homeostatic situation, IEC express negligent amount of 
TLR2, TLR4 and the LPS receptor CD14 (Abreu et al., 2001; Melmed et al., 2003; Lotz et al., 
2006). TLR5 is only located at the basolateral side of the cells, which limits its engagement to 
flagellin on bacteria that have penetrated to the lamina propria (Gewirtz et al., 2001). Other 
TLRs are located only on intracellular membranes, which together with the cytosolic NODs
make them oblivious to extracellular microbes (Abreu, 2010).
The effects of PRR activation in IECs are numerous: it increases the proliferative rate 
of the epithelium (Abreu, 2010) and stimulates secretion of some AMPs (Cash et al., 2006; 
Vaishnava et al., 2008; Brandl et al., 2007) as well as factors essential for mucus production
(Abreu, 2010). TLR2 activation preserves tight junction-associated barrier function (Cario et 
al., 2007). Engagement of IEC PRRs also affects lamina propria adaptive immune responses 
by facilitating secretion of BAFF and APRIL (Cerutti and Rescigno, 2008) and by allowing 
DCs to project between IECs to sample luminal antigens (Chieppa et al., 2006). As previously 
mentioned, PRR activation generally induces a pro-inflammatory transcriptional program.
However, in a landmark article by Rakoff-Nahoum et al. (Rakoff-Nahoum et al., 2004), it was
recognized that constant low grade IEC PRR activation is beneficial to the mucosa. As 
summarized in figure 3, abrogated PRR activation reduces epithelial responsiveness and 
leaves the mucosa more susceptible to pathogens and injury whereas excessive PRR 
INTRODUCTION
27
activation promotes inflammation with subsequent tissue damage (reviewed in (Asquith and 
Powrie, 2010))
Figure 3. Diminished or enhanced intestinal pattern recognition receptor (PRR) signals may 
promote intestinal inflammation and tumorigenesis. PRR signals are maintained at a critical 
threshold to maintain intestinal homeostasis. PRR signals may be required to restore barrier function 
after epithelial insult and for protective immunity against pathogens; impairment of these processes 
caused by insufficient PRR signaling may result in pathogen outgrowth and, indirectly, excessive 
subsequent inflammation (left). Excessive PRR-driven repair or inflammatory responses (right) may 
also threaten homeostasis, e.g., through dysregulated epithelial proliferation leading to tumorigenesis 
and overexuberant pathogenic inflammatory responses to the intestinal microbiota. 
©ASQUITH & POWRIE. 2010. Originally published in J.Exp.Med.207:1573-77.
2.3.3 Sectory immunoglobulins
IgA is the most prominent class of immunoglobulins in mammals. 80% of the antibody 
produced in the body originate from IgA-producing plasma cells (Brandtzaeg, 2009). Most of 
this IgA is produced in the gut as dimeric IgA (dIgA) covalently bound together by the J chain 
and transported from the stromal to the luminal side of the epithelium by the pIgR. It is 
estimated that in adult humans, 3 grams of dIgA is translocated in this fashion every day
(Brandtzaeg, 2009). In addition, some polymeric IgM is transcytosed by the pIgR
(Brandtzaeg, 2009), and IgG may also be secreted with the help of the neonatal Fc receptor
(Baker et al., 2009). IgA composes a minor fraction of serum Igs, but as it is by far the most 
abundant Ig class in mucosal secretions the following sections are devoted to an overview of 
mucosal IgA biology.
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2.3.3.1 IgA
The classical activation of B cells to become IgA-producing plasma cells takes place in 
GALT, primarily PPs but also in ILFs, and to some extent in MLNs, and is detailed in several 
reviews (Macpherson et al., 2008; Cerutti and Rescigno, 2008; Brandtzaeg, 2007) and 
summarized in the following paragraphs. A basic observation of IgA is that its production is 
dependent on the presence of microbial stimuli. IgA-producing cells are absent in neonates 
before colonization by commensal microbes, and they are reduced by 1-2 orders of magnitude 
in germ-free mice (Macpherson et al., 2008). The production of IgA requires the presence of 
intestinal microbes but most (>85%) of the produced IgA is polyspecific and recognizes
antigens from a wide range of microbes. The rest of the IgA displays single antigen 
specificities (Jiang, 2004; Strugnell and Wijburg, 2010).
The CCR7-binding chemokines CCL19 and CCL21 are expressed in PP and mediate 
extravasation of naïve B cells from the blood stream through high endothelial venules. In the
PP germinal centre the B cell encounters antigens which it engulfs with its BCR and 
subsequently digests and presents on its MHC II molecule. CD4+ T cells - already activated 
by DCs that present the same antigen as the B cell - recognize the specific MHC II-antigen 
complex on the B cell and subsequently allows CD40 on the B cell to ligate to CD40 ligand
(L) (CD154) on the T cell. In the crucial presence of TGF- the CD40-CD40L interaction 
induces the enzyme activation-induced cytidine deaminase (AID), which facilitates both class 
switch recombination (CSR) in the B cell from IgM or IgD to IgA and somatic hypermutation 
with subsequent enhanced affinity for the target antigen. Other substances like RA, inducible 
nitric oxide synthase, the innate switch factors APRIL and BAFF, and the cytokines IL-2, IL-
4, IL5, IL6, and IL-10 released in the germinal center also contribute to the activation and 
differentiation of intestinal B cells. It should be noted that in the PP, T cell-dependent 
activation of B cells may take place without the specific antigen recognition of the naïve B 
cells if the B cell is activated by PRRs (Suzuki and Fagarasan, 2009). This feature is not 
observed in peripheral lymph nodes and may contribute to the polyspecificity of IgA.
In parallel with CSR, RA  		! 					47 and 
CCR9 or CCR10. B cells leave the PP through the efferent lymphatics as IgA plasmablasts,
re-enter systemic circulation and are then directed to the intestinal lamina propria by 
interaction of 47 with MadCAM-1 and CCL25 with CCR9 (small intestine) or CCL28 with 
CCR10 (colon) on intestinal endothelial cells. In the lamina propria the plasmablasts undergo 
final differentiation to IgA-producing plasma cells.
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CSR may also take place in a T cell-independent fashion. Still in the presence of TGF-
, BAFF and APRIL released by DCs in ILFs may enable class switch and activation of B 
cells without CD40-CD40L interactions. As BAFF and APRIL may be secreted by IECs of 
the colon in a PRR-dependent fashion it is proposed that T cell-independent CSR may take 
place in the lamina propria (He et al., 2007) but this remains debated (Brandtzaeg, 2009).
In humans there are two gene loci which encode the IgA properties on the Ig heavy 
chain domain resulting in two subclasses of IgA, named IgA1 and IgA2. IgA2 is more 
resistant to bacterial proteases and is the subclass dominating as secretory IgA (SIgA) in the 
colon. IgA1 is the subclass dominating in serum and in all other mucosal secretions
(Brandtzaeg and Johansen, 2005). Mice only make one class of IgA, which structurally is 
equivalent to human IgA2 (Mestas and Hughes, 2004).
IgA (and IgM)-producing plasma cells in the gut also produce the J chain, which 
polymerizes IgA and IgM into dimers and pentamers, respectively. The transcriptional 
regulation of the J chain is poorly understood (Johansen and Brandtzaeg, 2004). The J chain is 
covalently linked by cysteine disufide bridges to two IgA heavy chain tail-pieces of opposing 
IgA monomers, which subsequently allows direct disulfide bonding between the penultimate 
cysteine residues of the two remaining heavy chain tail-pieces (Johansen et al., 2000).
Polymers of both IgA and IgM may form without the J chain but these are, along with the 
monomers, not substrates for pIgR-mediated transport (Johansen et al., 2000).
There are other IgA receptors than pIgR. Best characterized is the " (CD89) 
which is present on circulating myeloid cells like monocytes and neutrophils but not on gut 
mucosa resident APCs. This suggests that IgA may have a role in opsonization of antigens for 
phagocytosis in the systemic compartment (Otten and van, 2004). Other IgA receptors are the 
"#	! 			$			 	%						 		
transferrin receptor (CD71) expressed on human mesiangial kidney cells, and the 
asialoglycoprotein receptor expressed on hepatocytes. The significance of these receptors 
remains to be explored (2007).
The full biological role of systemic IgA is yet to be discovered. As opposed to IgM 
and IgG IgA does not activate compliment and is believed to play a homeostatic role (2007).
However, the main functions for IgA are believed to be related to the interaction with pIgR on 
mucosal membranes and are described in section 2.3.3.3.
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2.3.3.2 The polymeric immunoglobulin receptor
The pIgR is a ~100 kD protein produced by epithelial cells in literally all mucosal membranes 
but is particularly highly expressed in gut epithelium (Johansen and Brandtzaeg, 2004). It
consists of five N-terminal extracellular domains (D) where D1 hosts the ligand-binding site. 
It further has a single membrane- 		!			-cellular C-terminal tail which 
provides the routing information for the receptor (Macpherson et al., 2008) The PIGR gene is 
constitutively expressed, but also subject to regulation by cytokines, hormones, and microbes 
and MAMPs (Johansen and Brandtzaeg, 2004). Interestingly, both Th1 and Th2 cytokines, 
namely interferon (IFN)-
			 (TNF)-		-4 up-regulate pIgR 
expression in human intestinal epithelial cell lines. Activation of TLR3 and TLR4 also up-
regulated pIgR expression in vitro, suggesting a role for viruses and commensal microbes in 
the transcriptional regulation of pIgR (Schneeman et al., 2005). Accordingly, colonization of 
germ-free mice up-regulated pIgR expression in the small intestine (Hooper et al., 2001).
After synthesis in the endoplasmatic reticulum, the pIgR is delivered to the basolateral 
side of the epithelial cell where D1 binds non-covalently to the dIgA/J chain complex
(Johansen and Brandtzaeg, 2004). This binding promotes disulfide bonds between pIgR D5 
and cysteins residues 		&'		f the IgA (Johansen and Brandtzaeg, 2004). The 
pIgR/dIgA complex is then subjected to clathrin-mediated endocytosis, fused with 
endosomes, routed to the apical cell membrane, and finally cleaved by endoproteases on the 
cell membrane. A sketch of this transcytosis is shown in figure 4.  D1-5 of the pIgR, now 
termed secretory component (SC), together with the dIgA then forms SIgA (Macpherson et 
al., 2008).  The SC portion has a biologically important function on the SIgA complex as it 
makes the dIgA less susceptible to protelytic enzymes (Phalipon and Corthesy, 2003). The 
fact that mice with deleted pIgR gene have absent IgA in mucosal secretions demonstrate that 
the pIgR is solely responsible for the epithelial translocation of IgA (Johansen et al., 1999; 
Shimada et al., 1999). Further knowledge gained from studies in pIgR knock out (KO) mice is 
presented in section 5.2.1.
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Figure 4. Outline of pIgR-mediated transport of polymeric Igs. Dimeric (d)IgA or pentameric
(p)IgM, which is produced by plasma cells on the stromal side of mucosal membranesand held 
together by the J chain, is picked up by the polymeric immunolglobulin recetor (pIgR) on the 
basolateral side of epithelial cells. The dIgA- or pIgM-pIgR complex is then endocytosed, fused with 
endosomes, and transported to the luminal side where the extracellular domains of pIgR, a.k.a 
secretory component (SC), is cleaved off by endoproteases and the complex released in the lumen as 
secretory Ig (SIg). In addition, pIgR without an Ig cargo may travel the same route and be secreted as 
free SC. (Adapted from P. Brandtzaeg and F-E. Johansen)
In addition, pIgR that is not bound to dIgA may travel this same transcellular route and 
be cleaved off at the apical cell membrane and be released as free SC (Phalipon and Corthesy, 
2003) (Figure 4). SC is extensively glycosylated which facilitates retention in the 
glycosylated mucus layer. In vitro experiments have demonstrated that free SC binds and 
neutralizes Clostridium difficile toxin A (Dallas and Rolfe, 1998) and E.coli strains (de, I et 
al., 2001). It has also been shown in vitro that SC inactivates the neutrophil attractant IL-8
(Marshall et al., 2001). However, whether the free SC survives microbial proteolysis in the 
gut and plays a physiological role in mucosal homeostasis has remained enigmatic (Phalipon 
and Corthesy, 2003) Further research on free SC is warranted (Strugnell and Wijburg, 2010).
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Figure 5. Principles of pIgR/SIgA-mediated protection at mucosal surfaces. SIgA mediate 
mucosal homeostasis by (A) trapping luminal antigens in the apical mucus layer preventing the 
antigens to reach the epithelial cell membrane, by (B) re-routing intracellular antigens to the luminal 
side, by (C) neutralizing intracellular antigens preventing them from activating the epithelial cell, and 
by (D) transporting antigens from the stromal to the luminal side. (Adapted from P. Brandtzaeg and F-
E. Johansen)
2.3.3.3 The biological effect of SIgA
Conventionally there are three principle non-exclusive models for how SIgA exerts its effects: 
luminal immune exclusion, intracellular neutralization, and antigen excretion (Strugnell and 
Wijburg, 2010) (Figure 5). To assess the separate contributions of each of the three 
mechanisms in vivo is notoriously difficult. 
Immune exclusion refers to the concept that SIg is retained in apical mucus layer 
where it traps and agglutinates microbes (“flypaper”) and prevents them from reaching the 
epithelial surface (Figure 5a). This mechanism assumes that the IgA is polyspecific and that 
pre-formed IgA cross-reacts with different species because antigen-specific IgA takes weeks 
to be induced (Strugnell and Wijburg, 2010) Genetically modified  mice deficient in SIgA 
have been employed in various vaccine and infectious models with enteropathogens
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(reviewed in (Strugnell and Wijburg, 2010). Although the results vary among different 
models and studies are hampered by co-contribution of SIgM and IgG, the overall conclusion 
is that lack of SIgA renders animals less protected by vaccine and more susceptible to 
infections by enteropathogens. In addition, an elegant study demonstrated that mice deficient 
of SIg were more likely than mice with intact SIg to transmit S. typhimurium to wild-type 
littermates This suggests that SIgA may be important for herd immunity as shed bacteria are 
covered with a SIgA coat (Wijburg et al., 2006)
In vitro and in vivo studies have showed that dIgA-pIgR complexes can bind to 
intracellular viruses and antigens like LPS and reroute them back into the lumen and thereby 
prevent infection and mucosal inflammation (Brandtzaeg, 2007) (Figure 5b,c). Finally, in 
vitro and in vivo experiments have demonstrated that IgA may bind antigens, including whole 
viruses, in the lamina propria and excrete them to the luminal side by dIgA-pIgR-mediated 
transcytosis (Strugnell and Wijburg, 2010; Robinson et al., 2001) (Figure 5d).
In addition to eliminating microbes from the mucosal membrane, it is proposed that
SIgA carrying an antigen cargo may be trancytosed from the lumen to the lamina propria
through M cells. Reports from Corthesy and colleagues indicate that SIgA-antigen complexes
are then internalized in DCs, and this favors a tolerogenic DC respons (Corthesy, 2007). SIgA 
may thereby contribute to mucosal tolerance to commensal microbiota by supplying luminal 
antigens to DC without eliciting an inflammatory response. However, this model awaits for a
SIgA receptor on the M cells to be identified (Brandtzaeg, 2007).
2.3.4 Intestinal macrophages
Macrophages are leukocytes. Distinct from lymphocytes, they originate from the 
granulocyte/monocyte colony-forming unit, which differentiates to monocytes in the bone 
marrow, and the monocytes are then released into the blood. The monocytes may extravasate 
and differentiate in tissues to macrophages or certain DC subsets (Geissmann et al., 2010; 
Gordon and Taylor, 2005). Monocytes can be divided into subsets on the basis of surface 
markers. However, one has not been able to identify if certain monocytes subsets are 
committed to become macrophages and DCs, respectively (Gordon and Taylor, 2005; 
Geissmann et al., 2010). The local tissue factors responsible for the differentiation of 
moncytes to macrophages have not been identified (Gordon and Taylor, 2005; Geissmann et 
al., 2010). In the gut there is also a great overlap in functional characteristic and surface 
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markers between macrophages and DCs (Kelsall, 2008). Still, it is considered that gut lamina
propria resident macrophages functionally distinguish themselves from DCs in the same 
location by higher phagocytic capacity, increased intracellular killing, absent cytokine 
production, reduced antigen presentation, and inability to migrate to lymphoid tissue (Smith et 
al., 2010). Gut resident macrophages are non-proliferating and  long-lived; probably they live
for months after their final differentiation (Smith et al., 2010). Historically human 
macrophages have been identified by the cytoplasmic molecule CD68 (Pulford et al., 1990),
but lower expression of this marker may be shared with DCs and other cells types. Resident 
gut macrophages, but not inflammatory macrophages (see below), are rather characterized by 
their lack of common monocyte-associated markers as reviewed by Smith et al. (Smith et al., 
2010)
Resident gut macrophages express an array of TLRs, generally at a higher level than 
circulating monocytes, which enable them to distinguish self from microbes (Smith et al., 
2010). It has been shown that engagement of TLRs on resident macrophages may facilitate
the chemotaxis to and phagocytosis of various bacteria (Smith et al., 2010). However, in 
contrast to most monocyte-derived leukocytes TLR engagement in gut resident macrophages 
does not result in release of pro-inflammatory cytokines (Smith et al., 2010). This dampening 
of the inflammatory response is in particular mediated by TGF-, which is produced by 
epithelial cells, stromal cells, mast cells, and apoptotic T cells and is abundantly retained in 
the lamina propria extracellular matrix (Smith et al., 2010). Resident macrophages are crucial 
for clearing microbes and debris from the lamina propria without eliciting a full inflammatory 
response, which would cause unnecessary tissue damage. They are also important for 
production of extracellular matrix and for tissue repair (Smith et al., 2010; Mosser and 
Edwards, 2008).
In mucosal inflammation such as IBD, new monocytes are recruited to the intestinal 
lamina propria by chemotaxis. Chemokines produced by leukocytes, stromal cells and 
endothelial cells at the inflammatory site mediate recruitment of inflammatory macrophages,
which do not undergo suppressive differentiation like the resident macrophages but
differentiate like classically activated macrophages (Smith et al., 2005; Mosser and Edwards, 
2008). Hence, they generate a typical pro-inflammatory response with cytokines like TNF-	
and IFN-
. TLR engagement on these activated macrophages further increases the 
inflammatory response (Mosser and Edwards, 2008). Immunologically they express activation 
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molecules like CD40 and CD80/86 and Fc receptors for IgA and IgG (see (Smith et al., 2010)
for full list), which are all absent on resident macrophages in a homeostatic situation.
2.3.5 Regulatory T cells in the intestinal mucosa
Together with gut resident macrophages and IgA-producing plasma cells, CD4+ T cells 
constitute the majority of immune cells in the homeostatic gut mucosa. CD4+ T cells are 
commonly divided into the functionally distinct subsets Th1, Th2, and Th17, which all are 
regarded as pro-inflammatory, and Tregs that have immunosuppressive functions.
Tregs originate from the thymus or from naïve CD4+ T cells in the periphery. Tregs of 
thymic origin, so-called natural (n)Tregs, require high affinity interaction between TCR and 
MHC II on thymic stromal cells and co-stimulatory signals from CD40, CD28, IL-2 and IL-7
which together induce low levels of the Foxp3 that controls the suppressive transcriptional 
program of Tregs (Sakaguchi et al., 2010). nTregs are found circulating in peripheral blood
and in tissues. The TCR repertoire of nTregs is thought to have specificity to self as they are 
considered crucial for protection against autoimmunity (Curotto de Lafaille and Lafaille, 
2009; Sakaguchi et al., 2010).
In the gut lamina propria and lymphoid tissue, naïve Foxp3-CD4+ T cells may 
differentiate into Foxp3+ induced (i)Tregs. This induction requires TCR-MHC II interactions 
between naïve CD4+ T cells and conditioned DCs and a cytokine environment with sufficient 
IL-2, TGF-, RA and low levels of IL-6 (Curotto de Lafaille and Lafaille, 2009) (Figure 6).
Engagement of the co-stimulatory molecule cytotoxic T lymphocyte antigen 4 (CTLA-4) on
the T cell is essential for iTreg formation (Curotto de Lafaille and Lafaille, 2009). As 
previously discussed (see section 2.3.1) and sketched in figure 6, the DC subset and 
conditioning is important for the T cell differentiation. Pro-inflammatory DC conditioning 
and cytokine environment would differentiate the naïve T cells into pro-inflammatory Th17 or 
Th1 while other DC subsets and conditioning induce iTreg differentiation (Figure 6). Recent 
data indicate that Foxp3+ Tregs may lapse and become pro-inflammatory (Zhou et al., 2009; 
Murai et al., 2010). Gut iTregs have TCR specificities towards commensal microbes and 
dietary antigens (Curotto de Lafaille and Lafaille, 2009). In human gut mucosa nTregs and 
iTregs are indistinguishable and for the rest of this thesis they are collectively termed Tregs. 
In addition to Foxp3+ Tregs naïve CD4+ T cells may differentiate into Foxp3- T cells that have 
immunosuppressive capacities (i.e. Tr1, Th3) (Akbar et al., 2007).
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Figure 6. Regulatory network for intestinal CD4+ T cells. T helper 17 (TH17) cells are induced by 
transforming growth factor- ( 	
 		-6 (IL-6) and matured by IL-23 following the 
activation of intestinal dendritic cells (DCs) by phagocytosed microorganisms or stimulatory microbial 
molecules that have crossed the surface epithelial cell barrier and/or activated epithelial cells. The 
signature cytokines of TH17 cells, IL-17A and IL-17F, have pro-inflammatory effects and mediate 
neutrophil chemotaxis. TH17 cells also express IL-22, which contributes to epithelial homeostasis and 
stimulates the secretion of antimicrobial molecules. Acute inflammation is normally avoided through 
the induction of two classes of CD4+ regulatory T (TReg) cells that can be differentiated on the basis of 
their expression of the transcription factor forkhead box P3 (Foxp3). Foxp3+ TReg cells are induced by 
retinoic acid produced by CD103+  	  	   	 oxp3 TR1 cells are 
induced by IL-6 but inhibited by retinoic acid. TReg cells secrete IL- 	
  ! " 
negative regulatory effects on effector T cells. Commensal bacteria and their associated molecules 
also stimulate DCs to secrete IL-12, which activates interferon-# (IFN#) secretion by TH1 cells, which in 
turn activates phagocytic activity of subepithelial macrophages. NK, natural killer; TNF, tumour 
necrosis factor.
Reprinted by permission from Nature Publishing Group. Nature Reviews Immunology (Hooper & 
Macpherson) ©2010. 
In vivo experiments in mice have demonstrated that specific bacteria (Gaboriau-
Routhiau et al., 2009; Atarashi et al., 2011) or microbial products (Mazmanian et al., 2008; 
Donaldson et al., 2011) may induce Tregs. The TCR repertoire of Tregs in MLNs is distinct
from that in peripheral lymph nodes indicating that the intestinal antigens shape the intestinal 
Treg pool (Barnes and Powrie, 2009). How PRR engagement affects the induction of Tregs is 
not univocal. Mice that lack TLR2 seem to have reduced Treg numbers while TLR9-deficient 
mice demonstrate an alteration of the Treg/ Th17 balance in favor of an increase of Tregs
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(Curotto de Lafaille and Lafaille, 2009). It is also demonstrated that key bacterial species may 
alter the Treg/Th17 balance. Mice colonized with the ex vivo uncultivable anaerobes 
Segmented Filamentous Bacteria (SFB) have a reduced Treg/Th17 fraction in the small 
intestines (Ivanov et al., 2008; Gaboriau-Routhiau et al., 2009).
The identification of Tregs in humans has been heavily debated as no single cell 
marker exists to specifically detect all Tregs. In humans, the constitutive expression of CD25
(the high-affinity IL-'	 		(		&)*+ cells with concomitant expression of Foxp3 
is most often compatible with Tregs (Fontenot et al., 2003; Hori et al., 2003). However, both 
CD25 and Foxp3 may be transiently expressed on activated T cells in vitro (Buckner and 
Ziegler, 2008), and CD25 may even be expressed by activated  macrophages (Smith et al., 
2005). As mentioned above, Foxp3-CD4+ T cells with suppressive capacities may be present. 
Foxp3 is nevertheless considered the most relevant phenotypic marker for human Tregs. The 
crucial importance of this transcription factor in human gut homeostasis is demonstrated 
clinically when the FOXP3 gene is mutated. The ensuing syndrome of Immune dysregulation, 
Polyendocrinopathy, Enteropathy, X-linked (IPEX) displays an IBD-like enteropathy at 
infancy (Wildin et al., 2002). In addition to Foxp3 and CD25, other markers such as high 
expression of CTLA-4 and glucocorticoid-induced tumor necrosis factor receptor-related 
protein (GITR), combined with low expression of CD45RB and CD127, are all associated 
with CD4+ T cells exhibiting suppressive capacity in vitro. However, none of these markers 
alone shows better selectivity for Tregs than Foxp3 (Akbar et al., 2007; Josefowicz and 
Rudensky, 2009).
The mechanisms for Treg-mediated suppression in vivo have been poorly assessed, but 
in vitro experiments have provided some clues (Shevach, 2009). Tregs require specific 
stimulation of their TCRs and co-stimulation by IL-2, but once they are activated suppression 
is not restricted to MHC II engagement. Tregs mediate bystander suppression to other 
immune cells and suppress effector T cells by releasing immunosuppressive cytokines (e.g.
IL-10, TGF-	-35), by consuming IL-2 (through CD25), and by cell-to-cell contact 
mechanisms. They also inhibit immune activation by suppressing DC function through 
CTLA-4-CD80/86 and LAG-3-MHC II interactions. Treg-mediated suppression may take 
place both in the mucosa and in GALT and MLNs. Experimental colitis studies indicate that 
Treg suppression in lymphoid tissue is more important than suppression in the mucosa
(Barnes and Powrie, 2009).
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2.3.6 Host influence on gut microbes
The previous sections have provided examples from recent years’ intense research on how the 
commensal microbiota influences central elements of the host’s intestinal mucosal immune 
system such as epithelial cells, SIgA, macrophages, and regulatory T cells. There is now
increasing interest in how elements of the host immune systems reciprocally shape the 
intestinal microbiota.
It has been shown that monoassociating germ free mice with one microbial species
elicits a specific IgA response against this microbe (Talham et al., 1999; Hapfelmeier et al.,
2010) In a gnotobiotic model, Peterson et al. demonstrated that specific IgA inhibited the 
proliferation and fitness of a mutant Bacteroides thetaiotaomicron strain by modulating 
bacterial gene expression (Peterson et al., 2007). SFB induces a strong specific IgA respons
(Talham et al., 1999). Mice deficient in AID, and consequently lacking IgA, have an 
increased load of SFB, which can be reversed by reconstitution of IgA (Suzuki et al., 2004).
AID-deficient mice also have a general overgrowth of cultivable anaerobes (Fagarasan et al., 
2002). Peterson et al. have proposed a model where one of the main tasks of IgA and adaptive 
mucosal immunity is to recognize new epitopes expressed in the intestinal microbial 
community and thereby enforce a selective pressure on emerging strains and ensure diversity 
of the intestinal microbiota (Peterson et al., 2008). Thus, in addition to immune exclusion and
other functions of SIgA presented in section 2.3.3.3, SIgA shapes the composition of the 
intestinal microbiota and prevents dysbiosis.
Reports have also pointed out that elements of the innate immune system affect the 
composition of the intestinal microbiota. Lack of the PRR NOD1 		+,	-defensin in 
mice alters the composition of the microbiota without affecting the total number of gut 
bacteria (Bouskra et al., 2008; Salzman et al., 2010). Interestingly, in a mouse model it was 
reported that Gram negative bacteria could induce AMP that acted selectively on Gram 
positive bacteria. This finding suggests that intestinal microbes may employ innate immune 
elements in their internal colonization competition (Brandl et al., 2008). In another model, an
innate immune-deficient T-bet-/-Rag2-/- double knock out mouse developed spontaneous 
colitis which was transmittable to immune-competent mice (Garrett et al., 2007). It was later 
showed that the model favored colonization of the opportunistic pathogens K. pneumonia and 
P. mirabilis, which again were responsible for driving an UC-like disease (Garrett et al., 
2010).
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2.4 IBD etiology and pathogenesis
For long IBD has been considered a multifactorial disease occurring in genetically 
predisposed individual as a response to one or more environmental factors (Xavier and 
Podolsky, 2007; Baumgart and Carding, 2007). Although the full etiology of IBD has not
been unveiled there has been a tremendous improvement in the understanding of etiologic and 
pathogenic mechanisms over the last 15 years.
Among patients with CD and UC up to 22% and 15% of cases, respectively, have 
affected first-degree relatives (Baumgart and Carding, 2007). The concordance in 
monozygotic twins is 37% in CD and 10 % in UC which indicates that the genetic component 
is greater in CD than in UC (Baumgart and Carding, 2007). Almost 80% of affected families 
are concordant for one disease type (CD vs. UC) while the remaining 20% of families have a 
mixed disease phenotype (CD and UC). This indicates that there should be genes that 
predispose to only one of the disease types while other predisposing genes should be shared
(Cho, 2008). Genome-wide association studies have confirmed these predictions. Currently 71 
gene loci are associated with CD and about half of these are shared with UC (Franke et al., 
2010; McGovern et al., 2010).
The genes associated with the highest odds ratios (OR) for developing IBD are the 
NOD2 gene and a number of genes associated with autophagy and with the IL-23/Th17 axis. 
Mutations in NOD2, whose association is restricted to CD, confer loss of function in response 
to its ligand, muramyl dipeptide, which is present in peptidoglycan of both Gram positive and 
Gram negative bacteria (Cho, 2008). The close association between NOD2 mutations and CD 
strongly suggest disturbed host microbe interactions as an important cause of CD. The effect 
comes about through altered tolerance to chronic bacterial stimulation, impaired clearance of 
pathogens, or altered microbial colonization of mucosal surfaces (Cho, 2008). NOD2
mutations are also associated with reduced expression of -defensins in affected ileum of CD 
patients (Wehkamp et al., 2008). After NOD2 the innate immunity related genes with highest
OR for CD are the two genes ATG16L1 and IRGM that both are important for autophagy. 
Autophagy is an essential cellular process in which the cell degrades its own components and 
foreign bodies (e.g. microbes) and has recently been linked to NOD2 function (Travassos et 
al., 2010). Impaired autopahgy in CD patients further emphasizes the importance of the host’s 
proper handling of microbes at the mucosal surface.
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The overall closest association (OR 2.7 (Franke et al., 2010)) between gene mutations
and IBD is the IL-23 receptor (R) gene which is associated with both CD and UC and implies 
a role for adaptive immunity in IBD pathogenesis. There are multiple susceptibility alleles 
within the IL23R, of which some also confer protection from IBD (Cho, 2008). Furthermore,
several genes encoding signaling molecules downstream of IL23R are also associated with 
IBD (Cho, 2008). IL-23 is produced by activated DCs and is important for stabilization of 
Th17 cells (Bettelli et al., 2008) (Figure 6). Experimental mouse models have demonstrated 
IL-23’s importance in driving colitis (Sarra et al., 2010; Maloy and Kullberg, 2008). Th17
cells are increased in IBD lesions and considered to drive the mucosal inflammation (Sarra et 
al., 2010; Maloy and Kullberg, 2008).
Experimental animal models for IBD are generally dependent on the presence of 
intestinal microbiota (Uhlig and Powrie, 2009) and there is overwhelming clinical evidence 
that the intestinal microbiota is important for IBD pathogenesis (reviewed in (Sartor, 2008)). 
E. coli strains are more adherent and invasive in human IBD lesions. Antibiotics cure disease 
flares and probiotics may ameliorate the disease. IBD patients demonstrate serologic and 
cellular immune responses against gut microbes. New 16S rRNA phylogenetic microarrays 
and bacterial sequencing technology have also demonstrated a reduced diversity  and a shift in 
the composition of the intestinal microbiota where Proteobacteria (e.g. Enterobacteriaceae)
are increased at the expense of the phyla Firmicutes and Bacteriodetes (Frank et al., 2007; Qin 
et al., 2010). However, whether this shift is a cause or a consequence of the intestinal 
inflammation is still unknown. One recent report identified Faecalibacterium prasnitzii as a 
commensal that protect against CD (Sokol et al., 2008), but the full picture of key species that 
protect from or precipitate IBD remains to be determined.
IBD has several mucosal immunopathological features (reviewed in (Baumgart and 
Carding, 2007; Xavier and Podolsky, 2007). IBD patients have reduced epithelial barrier
function and downregulated tight junctions proteins, the mechanism (s) being unknown.
Impaired mucosal barrier function precedes the clinical symptoms and has been demonstrated
also in non-inflamed areas of the gut and in unaffected first-degree relatives of IBD patients.
Reduced AMP production by Paneth cells in the small intestines of CD patients have made 
some researchers claim that CD is primarily due to reduced microbial killing by AMPs
(Wehkamp et al., 2008). Also, epithelial cells have altered expression of PRRs in IBD 
patients. These observations all point to the importance of intestinal epithelial cell functions in
the development of IBD.
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As mentioned above, the gut mucosa of IBD patients has an increase of Th17 cells and 
their signature cytokine IL-17 (Sarra et al., 2010). Differentiation of Th17 cells is delicately 
balanced with peripheral induction of Tregs (see section 2.3.5) and dependent on the 
cytokines TGF-		-6. The close relationship with Th17 cells have suggested that Tregs 
may play an important role in IBD immune pathology (Xavier and Podolsky, 2007). Tregs are 
also increased in IBD lesions (Kelsen et al., 2005; Makita et al., 2004; Holmen et al., 2006; 
Maul et al., 2005; Saruta et al., 2007; Yu et al., 2007). Mice deficient in the 
immunosuppressive cytokine IL-10 develop colitis in the presence of commensal microbes. 
Recently it was also reported that a cohort of children with IBD had increased frequency of
mutations in the IL-10R gene, which underscore the significance of endogenous immune 
suppression for the prevention of IBD (Glocker et al., 2009).
As described in section 2.1.1 pediatric onset IBD differs clinically from adult onset 
IBD. For this reason it has been hypothesized that the etiology and pathogenesis of this entity
differ from adult onset disease (Kugathasan and Cohen, 2008; Kugathasan and Fiocchi, 2007).
So far studies on pediatric onset IBD have only recapitulated etiology and pathogenesis 
already demonstrated in adults (Kugathasan and Fiocchi, 2007; Henderson et al., 2011).
However, there is a lack of studies that have directly compared the immunopathology of 
pediatric and adult IBD patients, and such studies have been requested (Kugathasan and 
Cohen, 2008).
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3 AIMS OF STUDY
Main aim:
To explore mucosal immunopathogenic mechanisms in inflammatory bowel disease.
Aims :
1. To identify putative disparities between human pediatric onset and adult onset disease,
focusing on distribution of macrophages and regulatory T cells.
2. To elucidate interactions between secretory immunoglobulins and intestinal epithelial 
cell function and the intestinal microbiota in experimental animal models.
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4 SUMMARY OF RESULTS
4.1 Paper I
Increased number and activation of colonic macrophages in pediatric patients with 
untreated Crohn's disease. 
G. Perminow, D. H. Reikvam, L.G. Lyckander, P. Brandtzaeg, M. Vatn, and H. S. Carlsen.
Colonic and ileal biopsy specimens from untreated pediatric-onset IBD patients and pediatric 
non-IBD controls and colonic biopsies from untreated adult-onset IBD patients and their non-
IBD controls were examined by immunohistochemistry for the density of macrophages in toto
(CD68+) and for the density of activated macrophages (CD40+). Non-IBD adults had 
significantly higher density of colonic CD68+ macrophages than non-IBD children. Pediatric 
CD patients had significantly higher density of CD68+ macrophages in colon than pediatric 
UC patients and non-IBD controls. The density of activated (CD40+) macrophages was 
significantly elevated in both the colon and the ileum of CD children compared with non-IBD 
controls.
Conclusion: Histologically normal colonic mucosa has a higher density of macrophages in 
children than in adults. Activated mucosal macrophages are increased in untreated pediatric 
IBD regardless of inflammatory grade. This may reflect innate mucosal immune activation 
differences that contribute to different disease phenotypes in children and adults.
4.2 Paper II
Increase of Regulatory T Cells in Ileal Mucosa of Untreated Pediatric Crohn’s Disease 
Patients
D. H. Reikvam, G. Perminow, L. G. Lyckander, J. M. Gran, P. Brandtzaeg, M. Vatn, and H. 
S. Carlsen.
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Biopsy specimens obtained from colon and ileum of untreated pediatric-onset and adult-onset 
CD patients and from non-IBD controls were examined by immunohistochemistry with regard 
to markers associated with Tregs. The density of mucosal T cells displayed only small 
variations, while those of markers associated with Treg, Foxp3+ cells and CD25+ cells, were
increased in CD patients. Multicolor immunofluorescence showed that most CD25+cells were 
macrophages. In the ileum of pediatric CD patients the density of Foxp3+ cells was
significantly higher than in adult CD patients. Co-expression of Foxp3 and CD25, as well as 
Foxp3 and CTLA-4, indicated that the Foxp3+ cells were Tregs. .
Conclusion: Densities of mucosal Foxp3+ Tregs and CD25+ cells, the latter representing 
mostly macrophages, are elevated in both pediatric and adult ileal CD. The greater increase of 
ileal Foxp3+ Tregs in pediatric than in adult CD might contribute to the relatively less 
frequent phenotype of isolated ileal enteritis in CD children. 
4.3 Paper III
Depletion of murine intestinal microbiota: effects on gut mucosa and epithelial gene 
expression
D. H. Reikvam*, A. Erofeev*, A. Sandvik, V. Grcic, F. L. Jahnsen, P. Gaustad, K. McCoy, A. 
Macpherson, L. A. Meza-Zepeda, and F-E. Johansen.
* These authors contributed equally to this paper.
Germ-free animals represent a powerful approach to study bacterial-host interaction but are
not readily accessible to the wide scientific community. This study aimed at refining a 
protocol that would deplete the cultivable intestinal microbiota of conventionally raised mice 
as previously published protocols which administered broad-spectrum antibiotics in drinking 
water were difficult to reproduce. We show that twice daily delivery of antibiotics by gavage 
depleted mice of their cultivable fecal microbiota and reduced the fecal bacterial DNA load 
by 400 fold while ensuring the animals’ health and producing a macroscopic immune
phenotyping resembling germ-free mice. The antibiotic treatment significantly reduced the 
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expression of antimicrobial factors to a level similar to that of germ-free mice and altered the 
expression of 517 genes in total in the colonic epithelium
Conclusion:  We presented a robust protocol for depleting conventionally raised mice of their 
cultivatable intestinal microbiota with antibiotics by gavage and showed that the biological 
effect of this depletion phenocopies physiological characteristics of germ-free mice.
4.4 Paper IV
Altered mucosal homeostasis in mice lacking secretory antibodies
D. H. Reikvam, A. Erofeev, R. Islam, M. Derrien, V. Grcic, A. Sandvik, P. Gaustad,  L. A. 
Meza-Zepeda, F.L. Jahnsen, H. Smidt, and F-E. Johansen.
PIgR KO mice, which lack SIgs as a consequence of deleted pIgR gene and consequently 
abrogated epithelial transport of Igs to mucosal lumens, have no overt pathology but are 
thought to have an impaired epithelial barrier function. This genotype was used to study the 
significance of SIgs for colonic epithelial cell (EC) gene expression profile, intestinal 
microbial composition, and for induced experimental colitis. Microarray analyses of isolated 
colonic ECs revealed that 208 genes were >2-fold differentially expressed between pIgR KO 
and wt mice, and this number was reduced to 27 when the intestinal microbiota of both 
genotypes were suppressed by long term treatment with oral antibiotics. Phylogenetic 
microarray analyses of fecal samples and cecal biopsies showed that pIgR KO had a 
significantly altered composition of the intestinal microbiota compared with wt. PIgR KO had 
increased susceptibility to DSS-induced colitis compared with wt, but the morbidity of both 
genotypes were alleviated when the mice were depleted of their cultivable intestinal 
microbiota by antibiotic treatment, thus demonstrating that colitis was dependent on the 
presence of the microbiota.
Conclusion: PIgR and/or SIgs are crucial to maintain mucosal homeostasis and the microbial
composition in the gut. In case of an epithelial injury, the absence of pIgR/SIgs compromises 
the host’s ability to control inflammation and recover from colitis.
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4.5 Paper V
Absence of the polymeric immunoglobulin receptor protects B cell deficient mice from 
colitis.
D. H. Reikvam, A. Erofeev, A. Sandvik, C. Bang, E. Bækkevold, F. L. Jahnsen, and F-E.
Johansen
The physiological significance of unbound pIgR and free SC has not been determined. To 
assess pIgR’s role for colonic mucosal homeostasis independent of its SIg transportation 
properties pIgR KO mice were crossed with B cell-deficient (JH KO) mice to obtain a novel
pIgR; JH double knock out (DKO) mouse. DKO mice proved viable. After seven days of DSS 
induction JH KO mice showed aggravated morbidity compared with both the pIgR KO and
DKO strains. Untreated JH KO mice developed subtle spontaneous colitis with significant 
influx of Ly6G+ neutrophils at week 12 while this was not observed in pIgR KO or DKO mice
and could be reversed by concurrent oral treatment with broad spectrum antibiotics. In 
untreated mice, 8 out of 9 JH KO mice were euthanized due to weight loss by 22 weeks of age 
while the other strains remained healthy.
Conclusion: Absence of pIgR protects B cell-deficient mice from colitis and death. Studies to 
explore the mechanisms behind this observation are warranted.
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5 METHODOLOGICAL CONSIDERATIONS
This chapter discusses the main methods that have been used in the experimental work that is 
the basis for the submitted thesis. For a descriptive presentation of the applied materials and 
methods I refer to the methods’ sections of the individual manuscripts.
5.1 Human material
5.1.1 Patients
Papers I and II are studies based on patients included in the study Inflammatory Bowel 
Disease South-East Norway II (IBSEN II) (Perminow, 2010).
Patients in the pediatric arm of the IBSEN II study were all recruited at Ullevål 
University Hospital or Akershus University Hospital. The pediatric clinics of these two
hospitals have well-defined catchment areas, consisting of the city of Oslo and the northern 
and eastern part of the county of Akershus, respectively. This implies that all patients from 
these defined geographical areas referred to a pediatric hospital for assessment of IBD were 
evaluated at these two hospitals only. As all the pediatric patients consecutively included in 
the study between May 2005 and December 2006 were included in Papers I and II sampling 
bias should not be an issue. Moreover, all but three patients included were clinically and 
endoscopically evaluated by one physician (Dr. Gøri Perminow), and accordingly inter-
individual variation of patient and tissue specimen handling were minimized.
The adult patients, from whom tissue specimens for Paper I and II were obtained,
were randomly selected from the study database of patients included within the same time 
period as the pediatric patients. The numbers of patients specimens selected was based on a 
rational estimation of the numbers of patient necessary to demonstrate possible difference 
between the pediatric and adult patient groups in the immunohistochemistry (IHC)
investigations. Sampling bias in the adult patients groups cannot be ruled out and type II 
errors due to inadequate sample sizes are possible.
The symptomatic non-IBD control patients in the IBSEN II study have been subjected
to scrutiny. They were all initially referred to a gastroenterological specialist evaluation due to 
suspected IBD and consequently were not healthy at the time of examination. This fact
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provided both strengths and weaknesses to our investigations. As the control patients had 
IBD-like symptoms at the time of diagnosis they could potentially help reveal disease-specific 
IBD characteristics as opposed to pathogenic characteristics associated with diarrhea, 
abdominal pain, and other IBD-like symptoms. On the other hand, the symptomatic control 
group is a possibly heterogeneous group with concurrent gastrointestinal pathology that might 
have caused increased random bias. For adults one might have recruited healthy volunteers as 
controls. However, as pediatric patients have to be endoscoped under general anesthesia, a
sound clinical indication for the procedure had to be presented in order for the procedure to be 
ethically justified. Symptomatic patients in whom IBD was later excluded were therefore the 
only pediatric control group accessible for mucosal biopsy specimens.
The symptomatic non-IBD controls were diagnosed as irritable bowel syndrome or 
recurrent abdominal pain. Could these diagnoses have been preliminary, and could some of 
the control patients eventually have developed IBD at later time point? Excluding the 
possibility that study patients have moved out of the initial catchment area, none of the
pediatric control patients were diagnosed with IBD as of March 2010. (Personal 
communication, Dr. Gøri Perminow.)
5.1.2 Tissue specimen collection
Mucosal tissue specimens were collected with a forceps at the diagnostic endoscopy of each 
included patient. For diagnostic purposes multiple biopsies were collected according to a
predefined protocol. Tissue specimens specifically intended for the immunohistochemical 
investigations (Paper I and II) were collected and preserved additionally along with the 
diagnostic biopsies. The endoscopic appearance (inflamed vs. non-inflamed) and the gut 
location of each biopsy site was recorded by the examiner. When the immunohistochemistry 
studies started we decided not take this information into consideration for two reasons. First, 
the number of patients and tissue specimens were considered not large enough to justify 
comparisons between different regions of the colon, and therefore the only topical distinction
made was terminal ileum versus colon. Second, as the endoscopic appearance of the mucosa 
does not fully correlate with the histological degree of inflammation (Hommes and van 
Deventer, 2004), we decided to disregard the endoscopic inflammatory evaluation of each 
biopsy and only take into consideration the histological inflammation assessment.
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5.2 Animal models
Paper III, IV and V of this thesis are based on laboratory animal studies. Animal models are 
of great value to explore the biology of an integrated organism and the pathogenesis of a 
disease as well as to test new treatments for human disorders. Although in vitro studies are 
valuable for research on biologic mechanisms, they cannot recapitulate the full complexity of 
an integrated organism. 
Scientists are allowed to carefully inflict pathology on to animals and manipulate 
animals in ways that are considered unethical in humans. However, the ethics of laboratory 
animal research have received increasing attention over the last 50 years and can be summed 
up by the three R’s (Flecknell, 2002). Replacement: always consider other methodological 
approaches than animal studies to assess a scientific problem. Reduction: reduce the number 
of animals to the minimum. At the same time, scale the animal experiments big enough to 
allow robust statistical conclusions to be drawn; if not, the experiment and the animals used 
are wasted. Refinement: always make an effort to improve the conductance of the animal 
experiments in order to minimize the discomfort of the animals. It is recognized that adoption 
of the three R’s can improve the quality of the science (Flecknell, 2002). We strived to adhere 
to the three R’s in all animal studies performed for this thesis. All animal experiments were
approved by the National Animal Research Authority (Forsøksdyrutvalget) and conducted in 
accordance with the Norwegian Animal Protection Act of 1974 (repealed by the Animal 
Welfare Act Jan 1st 2010) and the Norwegian Regulation on Animal Experimentation. (2010)
Rodents in general, and mice in particular, are the most widely used laboratory 
animals as they are small, which make them easy to handle and transport and which minimize 
space requirements. Furthermore, they reproduce at high rate and are accessible for genetic 
modifications. Mice are clearly valuable as model organisms for human biology and 
pathology. However, all scientists should keep in mind that mice are not men and numerous
biological differences between the two species have been demonstrated (Mestas and Hughes, 
2004). Research results obtained in mice may not apply to man in general and must be 
validated in humans. Laboratory animal disease models generally do not recapitulate the full 
complexity of human disease.
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5.2.1 pIgR KO
To explore the role of SIgs in host-microbial cross talk and in experimental colitis (Paper IV 
and V) we based our studies on the pIgR KO mouse (Johansen et al., 1999). This genetically 
modified mouse was generated by Dr. Finn-Eirik Johansen and colleagues by disrupting exon 
3 of the pIgR gene, which encodes for the Ig binding site in D1. Analysis of mRNA from 
pIgR-/- mice indicated that a truncated receptor lacking D1 may be produced, but this does not 
possess any Ig-transporting properties (Johansen et al., 1999). Validation of the pIgR KO 
demonstrated that all epithelial transport of polymeric IgA and IgM was abrogated and that 
the pIgR KO had elevated serum IgA (mostly polymeric) and IgG (Johansen et al., 1999).
Further studies have shown that the pIgR KO have increased numbers of IgA secreting cells 
in lamina propria (Uren et al., 2003) and in the MLNs, PPs, and spleens (Sait et al., 2007).
Oral tolerance could be induced in the pIgR KO to the same degree as WT controls and initial 
tests of inducible immune functions was unaltered (Uren et al., 2003; Karlsson et al., 2010).
Several studies have later demonstrated that the pIgR KO elicits strong serum responses to 
various microbial antigens (Wijburg et al., 2006; Uren et al., 2005; Cunningham et al., 2008; 
Maaser et al., 2004; Sun et al., 2004; Davids et al., 2006; Sait et al., 2007).
Bacterial cultivation (Sait et al., 2007) and denaturing gradient gel electrophoresis
(Sait et al., 2003) of  ileal biopsies from co-housed pIgR KO and C57BL/6 controls did not 
reveal any differences in microbiota composition. However, use of newer gene sequencing 
and microarray-based techniques would have provided superior resolution to these 
assessments.
The initial characterization of the pIgR KO revealed that it had no overt pathology and 
was of normal size and fertility. Histopathologic evaluation of the intestines showed no 
pathology. However, it had increased IgG and albumin in mucosal secretion compared with
wild type (WT) controls, which is interpreted as increased epithelial protein leakage
(Johansen et al., 1999). Furthermore, the pIgR KO had increased titers of E. coli-specific IgG 
indicating systemic immune stimulation in the abscense of SIgs (Johansen et al., 1999). This
finding was later reproduced and the notion was reinforced with the observation that MLN of 
pIgR KO harbor more viable bacteria than WT controls (Sait et al., 2007). In summary, it is 
believed that the pIgR KO has an epithelial membrane barrier defect due to its lack of SIg that
renders it vulnerable to microbial or toxic stress and more susceptible to develop colitis.
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As experiments reported in Paper IV were launched, a paper comparing 
conventionally raised pIgR KO with IgA KO and WT C57BL/6 in the DSS colitis model was 
published (Murthy et al., 2006). This article showed that the pIgR KO was more susceptible 
to DSS than both IgA KO and WT controls. 
The pIgR KO has been employed in various infection models. It has been shown to be 
more susceptible to Vibrio cholera toxin challenge than C57BL/6 controls, even after 
vaccination, while vaccination against Salmonella typhimurium offered protection against
recurrent infection equally well in both the pIgR KO and the C57BL/6 (Uren et al., 2005).
Unvaccinated pIgR KO had a lower threshold dose for surviving infection with Salmonella 
typhimurium and shed more bacteria than C57BL/6 pointing at a putative role for SIg in herd 
immunity (Wijburg et al., 2006). In contrast, two reports found that pIgR KO cleared 
Citrobacter rodentium and an attenuated Salmonella sp., respectively, at the same rate as WT
controls (Maaser, 2004; Endt et al., 2010). The inconsistency of these results may reflect
differences in the size of the enterobacterial inoculums. The pIgR KO had also increased 
susceptibility to Giardia muris, but not Giardia lamblia (Davids et al., 2006). Outside the gut
the pIgR KO has been shown to be more susceptible to chlamydial prostatitis (Cunningham et 
al., 2008) and to nasal colonization by Streptococcus pneumonia (Sun et al., 2004).
In parallel to and independent of Dr. Johansens development of the pIgR KO, a
Japanese group made another pIgR KO by deleting exon 2 of the pIgR gene (Shimada et al., 
1999). This Japanese pIgR KO confirmed the findings in Dr. Johansens pIgR KO with 
abrogated transcellular transport of dIgA with subsequent increased levels of serum dIgA. In 
the Japanese pIgR KO some of the results obtained in Dr. Johansen’s pIgR KO have also been 
recapitulated such as increased susceptibility to cholera toxin challenge (Tokuhara et al., 
2010), reduced cross-protection between a selection of influenza viruses (Asahi et al., 2002; 
sahi-Ozaki et al., 2004), and increased susceptibility to Mycobacterium tuberculosis
(Tjarnlund et al., 2006) All of these features occurred despite robust responses to vaccination 
in terms of antigen specific serum IgA and IgG levels.
In conclusion, with its assumed leaky epithelial barrier and its reduced ability to cope 
with microbial pathogens in spite of good inductive immune responses, we believed that the 
pIgR KO would be of interest to study in a colitis model, and, furthermore, we considered this 
approach to be valid for investigating SIgs and pIgR/SCs role in protection against colitis.
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5.2.2 Genetic background
The pIgR KO was originally created by injection of embryonic stem cells from the inbred 129 
strain into C57BL/6 and then backcrossed to C57BL/6. It was later backcrossed over 10 
generations to the inbred albino strain BALB/c by Denis Meztger (pers.comm. F-E. Johansen) 
and transferred to Taconic Farm Inc’s emerging models program from where it is now 
commercially available. Several of the pilot studies for Papers III and IV were performed on 
C57BL/6. However, we eventually decided to convert the main experiments to BALB/c for 
three reasons. First, the BALB/c background was chosen for other projects that required a Th2 
skewing, which the BALB/c strain provides. Applying the same strain for the colitis 
experiments would therefore reduce the breeding colonies. Second, as DSS experiments with 
the pIgR KO on C57BL/6 background had already been published (Murthy et al., 2006),
conversion to BALB/c background would provide novelty to our colitis experiments. Third, 
the JH KO (see section 5.2.3) that we intended to cross the pIgR KO onto was readily 
available on BALB/c background.
The albino trait is caused by spontaneous mutation affecting tyrosin kinase, an enzyme 
required for melanin production. The mutated enzyme may also be involved in numerous 
other physiological functions (Hem A et al., 2004). Of note for immunologists, BALB/c mice 
are well known for their strong development of Th 2 type responses (Chen et al., 2005).
Important to our colitis experiments, BALB/c have been shown to be susceptible to DSS
(Melgar et al., 2005) and consequently provided a  suitable genetic background for studying 
the pIgR KO in the DSS colitis model.
BALB/c mice are commercially available in several substrains. All our BALB/c were 
provided by Taconic Farms’ plants in New York and in Tornbjerg, DK. For our studies any 
further substrain specifications were disregarded.
5.2.3 JH KO and DKO
In Paper V we wanted to assess the innate significance of pIgR uncoupled from its Ig 
transporting properties and the role of SC without luminal Igs. JH KO was purchased from 
Taconic Farms and crossed with the pIgR KO to produce a pIgR/JH double KO (DKO). To 
our knowledge this crossing has previously not been described. The JH KO was developed by 
deleting the four J segments of the Ig heavy chain locus (Chen et al., 1993). This causes 
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aborted V (D)J recombination of the Ig variable region, and consequently no functional B cell 
receptors or Igs are produced. 
The JH KO has been employed in numerous studies on B cell dynamics but very few 
studies on B cell deficiency and colitis have been reported. One study investigated the colon 
of JH KO up to 40 weeks of age and found macroscopically and histologically normal colons
and recorded no weight loss, diarrhea or premature death (Ma et al., 1995). This same study 
crossed the JH KO onto IL-2 KO, which aquire spontaneous colitis, and showed that the JH/IL-
2 double KO got colitis to the same degree as the IL-2 single KO. Another paper reported 
normal litter sizes, body weight, and no protein-losing enteropathy in JH KO (Slack et al., 
2009). By employing another B cell-deficient mouse (Igµ-/-) in the spontaneous TCR-/- colitis 
model it was shown that B cells had a protective role (Mizoguchi et al., 1997; Mizoguchi et 
al., 2000). In summary, experimental colitis studies have shown that the role of B cells, if any, 
is a beneficial one.
The target genetic model that we looked for when we acquired the JH KO was one that 
did not produce any Igs, but elsewise was as immunologically normal as possible. B-cell 
development is disrupted at an early stage in the JH KO, which may result in abrogation of 
other functions of B cells than differentiation to plasma cells and Ig production (Lund and 
Randall, 2010). As alternatives to the JH KO we considered to acquire the RAG2-/- to cross 
breed with the pIgR KO. However, the RAG2-/- also have an absent T cell compartment, and 
we therefore considered it less suitable. We also discussed to cross breed the pIgR KO with 
the J chain KO. This model has mature B cells, plasma cells, and produces Igs of all classes 
but has impaired ability to polymerize IgA and IgM and therefore lacks the ligands for pIgR
(Hendrickson et al., 1995). However, the J-chain KO model is shown to be “leaky” in the way 
that it has some IgA and IgM in feces and bile (Hendrickson et al., 1995), and it would not 
rule out the potential contribution of luminal IgG, either by passive diffusion or facilitated by 
the FcRn transporter (Baker et al., 2009). All together, we judged the JH KO as the most 
specific model of the available alternatives.
5.2.4 Breeding strategy
Breeding colonies for pIgR KO and BALB/c mice for the DSS experiments in Paper IV were
kept in one SPF facility at Taconic Farms, Ejby, DK and adult age-matched male mice were 
shipped from those colonies. We emphasized that the pIgR KO and BALB/c controls should 
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be bred within the same barrier facility to avoid systemic bias in terms of different microbial 
environment.
All other animal experiments (Papers III-V) were performed on in-house bred mice. 
Twelve JH KO females from Taconic Farms, Germantown, USA and four pIgR KO males 
from Taconic Farms, Ejby, Denmark, both on BALB/c background, were purchased as 
founders and mated to produce F1 hybrids that were double heterozygotes with regard to pIgR
and JH. The F1 hybrids were then sibling mated and the four different double homozygote 
variants pIgR-/- JH+/+ (termed pIgR KO), pIgR+/+JH-/- (termed JH KO), pIgR-/-JH-/- (termed 
DKO), and pIgR+/+JH+/+ (termed WT or BALB/c) were selected and continuously bred as 
homozygotes over ten generations. The breeding took place in filter top cages with enclosed 
ventilation placed in one rack in a minimal disease barrier facility, which was under strict 
health monitoring and free of FELASA-defined pathogens in sentinel animals. All animals 
employed in our experiments were within 10 generation of the founders. Outside a 
gnotobiotic facility we believed this was the best effort to conserve a uniform microbial
environment for the breeding colony as a whole.
The breeding strategy for obtaining the theoretically optimal control animals, in terms 
of genetic and environmental uniformity to the study animal, would be to mate double 
heterozygotes and use offspring littermates in experiments. However, as only 1/16 offspring 
from a double heterozygote mating would be double homozygotes and the average litter size 
was approximately six, this breeding strategy was not feasible. As we wanted to use gender 
matched animals in experiments comparing pIgR KO and WT controls only, mating pIgR+/-
for these experiments was also considered not feasible.
5.2.5 DSS colitis model
In Paper IV and V we applied the DSS colits model, an experimental animal model for 
ulcerative colitis. Several animal models of IBD have been published. These animal models 
fall into four categories: spontaneous development of intestinal inflammation, induction of 
colitis by genetic manipulation, induction of colitis by administration of exogenous chemical 
compounds, and finally transfer of defined cell population into an immunodeficient host
(Blumberg et al., 1999). Of note, with a few exceptions, all experimental colitis models
require the presence of an intestinal microbiota. Some models even have specific 
microbiological requirements for colitis to occur (Uhlig and Powrie, 2009). As the pIgR KO 
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does not develop spontaneous colitis, we had to find a model based on administration of a
chemical compounds. Of the two most frequently applied models within this category, the 
DSS and the trinitrobenzene sulfonic acid (TNBS) models, we chose the DSS model due to its 
technical simplicity. DSS can be administered in drinking water as opposed to administration
of TNBS which is dissolved in ethanol and applied through enema and consequently requires
sedation of the mice. Moreover, the validity of the DSS model is better than the TNBS model 
as a study of the gene expression profile of the distal colon showed that 15 out of 32 genes 
that are known to be differentially expressed in IBD were also differentially expressed in the 
DSS colitis model while the same fraction for the TNBS model was 2 out of 32 (te Velde et 
al., 2007).
DSS is a sulfated synthetic polysaccharide and is produced in different dextran sizes. 
For all our experiments we used the 40 kD dextran purchased from the same vendor, which is 
the widely used product for the rodent colitis model, and which is shown to induce the most 
sever colitis (Kitajima, 2000). DSS ability to induce colitis may be related to the total sulphur 
contents of each dextran molecule (Kitajima, 2000). Our experiments were performed with 
DSS with a sulfur content of 17% according to the manufacturer.  Larger dextran molecules 
do not produce colitis, presumably due to reduced ability for the larger dextran molecules to 
penetrate to the mucosal membrane (Kitajima, 2000).
The DSS colitis model was first described by Okayasu et al in 1990. It was considered 
a valid model for UC due to its clinical and pathological resemblance to the human disease.
Mice subjected to the protocol suffer weight loss, diarrhea, and occult and gross blood in 
feces, which correlate with multiple mucosal erosions and inflammatory infiltrates, all 
confined to the colon and more prominent in the distal part (Cooper et al., 1993; Okayasu, I, 
1990). The relevance of the model has also been demonstrated by the fact that drugs of all 
classes used in the treatment of human IBD also ameliorates DSS-induced colitis (Murthy et 
al., 1999; Axelsson et al., 1998; Bjorck et al., 1997; Melgar et al., 2008).
The molecular and cellular mechanisms for how DSS induces colitis have been 
explored, but are still not clear. It has been shown that DSS can induce colitis in the absence 
of adaptive immune cells (Dieleman et al., 1994; Axelsson et al., 1996), and it has further
been reported that DSS affect the function of macrophages (Okayasu, I, 1990; Ohkusa et al., 
1995) and dendritic cells (Berndt et al., 2007), pointing at a role for innate immunity.
However, the mantra has been that DSS exerts its pathogenic effect by disrupting the 
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epithelial barrier. Early studies pointed to a direct cytotoxic effect of DSS on the epithelial 
cells and that DSS interfered with the normal interactions between IECs and intraepithelial 
lymphocytes (Ni et al., 1996). In line with this notion, it has been demonstrated that increased 
mucosal permeability can be observed prior to erosions and inflammatory changes (Kitajima, 
1999) and this coincides with an alteration of tight junction proteins in the epithelium (Poritz 
et al., 2007). A recent report demonstrated that DSS after 12 hours’ exposure compromised 
the inner mucus layer’s ability to prevent luminal bacteria from reaching the epithelial cells,
suggesting that the mucosal inflammation is driven by commensal intestinal bacteria rather 
than a direct toxic effect of DSS on the epithelium (Johansson et al., 2010).
The significance of the intestinal microbiota in the propagation of DSS colitis has been 
demonstrated at several levels. The original presentation of the DSS colitis model reported a 
shift in the composition of the gut microbiota following DSS colitis (Okayasu, I, 1990).
Several reports have later demonstrated the protective effect of probiotics (Schultz, 2004; 
Fujiwara, 2003; Osman et al., 2004; Herias et al., 2005; Mennigen et al., 2009) or sonicates of 
intestinal microbiota (Verdu et al., 2000) on DSS colitis. Systemic administration of 
antibiotics is reported to attenuate DSS-induced colitis (Hans et al., 2000) while full depletion 
of the intestinal microbiota by orally administered antibiotics increased the mortality after 
DSS exposure (Rakoff-Nahoum et al., 2004; Hudcovic et al., 2001). Reports on DSS 
administration in germ-free animals are somewhat conflicting as some have reported 
decreased susceptibility (Hudcovic et al., 2001) while others have reported increased 
susceptibility (Bylund-Fellenius et al., 1994) to DSS. This may be due to differences in the 
concentration of the administered DSS. Also, the phenotype of the morbidity related to the 
increased mortality in germ-free mice is different from that in conventional mice (Kitajima et 
al., 2001). It is therefore proposed that DSS may induce two different types of intestinal 
pathology: i) colitis that is dependent on the presence of bacteria; and ii) a hemorrhagic-type 
mucosal destruction, in which the intestinal microbiota has a protective role.
Another intriguing feature of the DSS colitis model is the variation of DSS 
concentrations used by different researchers, ranging from 1.5% to more than 5%. To some 
extent this may be due to the fact that different experimental approaches demand different 
immediacy and severity of colitis. The concentration, but not the consumed dose, of the 
administered DSS correlated with the histological severity in one report (Egger et al., 2000).
Animal strain, sex, and age may also affect the susceptibility to DSS. However, frequently 
conveyed by word between researchers but rarely reported in manuscripts is the variable 
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susceptibility to DSS also within research labs, both in space and time. We have experienced 
that performing identical DSS experiments in two different corridors within the same animal 
barrier facility gave different results, and that the response to DSS in the same animal room
fluctuated over time. We therefore believe that all DSS experiments should be interpreted
with a spatial and temporal specificity. All the DSS experiments included in this thesis were 
performed with the same DSS concentration in same animal barrier within one year of time.
Though difficult to assess, most researchers believe the variable response to DSS is caused by 
variations in the intestinal microbiota.
Mice employed in the DSS experiments were intended to be stabled two and two in 
each cage due to animal welfare. As we used males only it restricted the possibility to regroup 
mice from different litters, with the consequence that a mouse from a litter of odd numbered 
males was stabled alone. Each animal was defined as an experimental unit, but this could be 
debated considering environmental confounders within in a cage. Defining each cage as one
experimental unit would have required a doubling of the number of animals used.
Mice from litters were stratified to the different experimental groups in order to 
minimize systematic bias. The individual mouse was randomly picked to the experimental 
group that an animal from its litter was stratified to. 
We considered it not feasible to blind the performing researchers to the genotype or 
experimental treatment of each cage. The daily read-out of the experiments was weighing of 
mice, which should not be subject to examiner bias. The other parameters evaluated by the 
researchers were diarrhea and gross blood from anus. Coherent definitions were made for 
these assessments in order to reduce examiners bias. All organ evaluation upon sacrifice (e.g. 
colon length, Payer’s patches assessment) was performed by a technician who was kept 
blinded for the genotype and the treatment of the individual mouse.
5.3 Histopathology
Papers I, II, IV, and V all includes histopathological assessments of intestinal mucosal 
tissue. Biopsies were cut with a predefined thickness and stained with hematoxylin and eosin
before being evaluated by a trained histopathologist. Histopathological evaluation of tissue 
morphology is by nature a qualitative assessment. To compare the morphology of different 
biopsies we applied previously published scoring systems, which quantified the degree of 
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inflammation of the individual biopsies. We applied the scoring systems in the same species 
and for the same diagnosis and experimental approach as the ones they were based upon
(Siegmund et al., 2001; Rugtveit et al., 1997).
All slides were blinded and assigned a random examination number to mask the 
identity and diagnosis of the slides and to scramble the order in which they were examined. 
This should prevent systemic bias of the scoring due to unconscious drift of the scoring 
throughout the examination.
To assess the intra-individual variability of histopathologic scoring the slide sets were 
in part reevaluated in a blinded fashion by the same histopathologists. For the scoring 
described in papers I and II the histopathologist had a diagnostic reproducibility of 83%. For 
the inflammation score in the DSS treated mice in paper V, the histopathologist had a 79% 
reproducibility rate for the individual scoring factors. Both numbers are considered acceptable 
for intra-individual variability with regard to a clinical histopathologist’s assessment of 
inflammation (personal communication, Lars Gustav Lyckander).
5.4 Immunohistochemistry
Papers I and II are entirely based on data obtained by immunohistochemistry (IHC) and 
papers III and V presents some data based on this method. IHC takes advantage of the 
specific recognition of an antigen by an antibody (immunoglobulin). As the target protein –
the antigen - is fixed in its natural place in the tissue, IHC provides spatial information on the 
distribution of the antigen, which is the major advantage of IHC compared with ELISA or 
Western blotting technices. The principles for IHC have been extensively described
(Brandtzaeg, 1994) and are outlined in figure 7 and 8.. However, a few key issues deserve 
consideration.
Although antibodies used in IHC bind specifically to a target antigen, unspecific 
staining does occur. This can be caused either by specific antibody recognition of an antigen 
present on a protein other than the target protein (cross reaction), or by unspecific binding of 
any elements in the IHC protocol to the target tissue (noise). To assess the contribution of 
noise in the IHC staining we always included a control staining that was incubated with an 
irrelevant primary antibody but otherwise was treated identical as the target staining.
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There are two principles for production of antibodies. Polyclonal antibodies are 
purified from serum of immunized animals and will generally possess reactivity to several 
epitopes on the target protein. Monoclonal antibodies are produced by a clonal population of 
hybrodoma cells generated from fusion of a single B cell with an immortal myeloma cell. 
Polyclonal antibodies are considered to be more sensitive than a monoclonal antibody, but 
they are also more prone to react with epitopes shared by other proteins than the target 
protein, and are therefore more susceptible to give unspecific staining (cross reaction) in IHC.
Monoclonal antibodies only react with one epitope on the target protein. Naturally 
they are therefore not as sensitive as polyclonal antibodies, but their specificity is generally 
better. However, the epitope recognized by a monoclonal antibody may be shared by other 
proteins so the specificity of new monoclonal antibodies should always be validated on tissue 
specimens by comparing the staining pattern with that of other well-tested antibodies.
Monoclonal antibodies will also be of a specific IgG subclass (or other isotype), which widens 
the range of possibilities for multistaining on one slide as secondary antibodies targeting a 
specific IgG subclass have become available.
Cell
Primary antibody of the subclass IgG1
recognizing antigen A
Enzymatically labelled secondary antibody 
recognizing primary antibody of the IgG1 
subclass
Cell
AB
Substrate for enzyme
Product visualized in light microscope
Figure 7. Immunohistochemistry 1. Principle of enzymatic detection of immunostaining method 
applied in papers I and II. The primary antibody specifically recognizes antigen A and not antigen B.
(Adapted from I. Heier)
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Several aspects of the examined tissue specimens are important for the accessibility of 
the antigen-antibody immune reaction that forms the basis of IHC. Traditionally, IHC has 
easiest been performed on cryopreserved specimens, which are fixed in acetone or alcohols
after sectioning. This tissue preparation retains most epitopes available for antibody detection, 
but does not preserve tissue morphology as well as formaldehyde-based fixatives. 
Formaldehyde forms protein-protein and protein-nucleic acid methylene cross bridges, which 
ensures good tissue morphology but often masks epitopes. This can be overcome by 
immersing the formaldehyde-fixed tissue section in buffers at boiling temperatures prior to
the IHC (Montero, 2003). The acetone or alcohol fixatives offer another advantage over 
formaldehyde as they disrupt the lipid bilayers of cell membranes, which open up for antibody 
penetration and intra-cellular immunostaining (e.g. Foxp3). Formaldehype-fixed section must 
be treated with a detergent to allow for intra-cellular staining.
Cell
A B
Primary antibody of the subclass IgG1
recognizing antigen A
Primary antibody of the IgG2a subclass 
recognizing antigen B
Fluorescent secondary antibody recognizing 
primary antibody of the IgG1 subclass
Fluorescent secondary antibody recognizing 
primary antibody of the IgG2a subclass
Figure 8. Immunohistochemistry 2. Principle of fluorescent detection of immunostaining applied in 
papers I-III and V. One primary antibody specifically recognizes antigen A and not antigen B, and the 
other primary antibody specifically recognizes antigen B but not antigen A. By conjugating different 
fluorescent dyes to the specific secondary antibodies multiple antigens can be detected 
simultaneously. (Adapted from I. Heier)
For all formaldehyde-fixed tissue we carefully tested antigen retrieval protocols.
Primary and secondary antibodies were titrated to determine the maximum signal-to-noise 
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ratio, which is the concentration of antibody that provides the least unspecific background 
staining (noise) without reducing the signal from the target antigen (signal).
Detection of bound target is mediated either by an enzymatic reaction (as in figure 7)
or by fluorescence (as in figure 8). In papers I and II we used horseradish peroxidase (HRP) 
enzyme polymers conjugated to the secondary antibody. These HRP polymers produced a 
brown color when substrate was added. Enzyme-based detection techniques offer the 
advantage that the sections can be counterstained with eosin, which gives a better orientation 
of the morphology. These techniques are generally more accessible as they are evaluated by 
light microscopy. A disadvantage of HRP-based detection is that tissue may contain
endogenous peroxidase activity, but this can be overcome by blocking agents. However, the 
blocking agent may also destroy the target epitope. We therefore applied two alternative 
blocking agents for the HRP-based IHC. All papers except paper IV also include IHC 
experiments that applied fluorescence as the detection mode. Apart from reducing the need 
for blocking of endogenous enzyme, fluorescence-based detection more readily offers the 
possibility of detecting several antigens simultaneously by multi-color fluorescence (Figure 8) 
and still allowing the individual target antigens to be evaluated separately by filtering the 
fluorescent emission in the microscope. Disadvantages of fluorescence-based detection are
that it requires special microscopes and that the fluorescent dye inevitably will fade, which 
reduces the longevity of the IHC fluorescent staining.
IHC is by nature a qualitative method. However, by counting the number of positive 
signals and relating that to a fixed measure one can obtain quantitative data from IHC. We 
generated quantitative continuous data from IHC by relating positive signals (cells) to the area 
of the examined section (paper I and II), to a defined micro-anatomical structure (e.g. crypt 
or colon cross section) (paper III and V), or as a fraction of positive cells co-expressing the 
target marker in two-color staining (paper II). All quantitative evaluations of the IHC 
stainings were performed with the examiner blinded to the specimen identity and in a
randomized order.
The following paragraphs provide a brief presentation and validation of the markers 
used for IHC.
CD68. CD68 is a highly glycosylated transmembrane protein belonging to the lamp 
family of proteins and located in the endosomal compartment of the cytoplasm (Holness and 
Simmons, 1993). Unlike other lamp family proteins, which are ubiquitously expressed in all 
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cell types, CD68 has been considered a marker restricted to the monocyte/macrophage lineage
(Pulford et al., 1990). For several years it has been known that some monoclonal antibodies 
against CD68 may cross-react with other myeloid cells (Pulford et al., 1990) and over the 
years some clones have even showed reactivity to non-hematopoietic cells. Accordingly
scientists have questioned the specificity of several anti-CD68 antibodies as macrophage 
markers (Gottfried et al., 2008; Kunisch et al., 2004). However, no other marker has been 
proposed as the pan-macrophage marker. The function of CD68 is not known.
CD40. CD40 is a receptor located on the plasma membrane of B cells, APCs including 
macrophages, and has also been described on non-hematopoietic cells like epithelial,
endothelial, and mesenchymal cells. Its ligand is CD40L (CD154), which is preferentially 
expressed on activated CD4+ T cells and on activated platelets. Engagement of the 
CD40/CD40L system on APCs activates these cells to express other co-stimulatory molecules 
and to produce pro-inflammatory cytokines. Expression of CD40 is shown to be upregulated 
in several mucosal cell types in IBD (Carlsen et al., 2006; Danese et al., 2004; Hori et al., 
2003; Fontenot et al., 2003).
CD3. As a protein complex required for the cell surface expression and signaling of 
the T cell receptor, CD3 is the undisputed restricted T cell pan-marker.
Foxp3. Several publications from 2003 showed the transcription factor Foxp3 to be 
linked to CD4+CD25+ T cells with immunosupressive capacities (Fontenot et al., 2003; Hori 
et al., 2003). However, intense research on human Tregs over the last decade has 
demonstrated the complexity of Foxp3 and Tregs. On the one hand peripheral blood in 
humans contains Foxp3+ T cells that do not confer suppressive capacities, but if this is the 
case in intestinal tissue is unknown (Sakaguchi et al., 2010). Also, in vitro stimulation of 
naïve T cells has produced transient expression of Foxp3 in cells that eventually display a pro-
inflammatory phenotype, but if this has relevance for in vivo T cell dynamics is debated
(Sakaguchi et al., 2010). Recent reports point out that high expression of Foxp3 in T cells 
confer high suppression in vitro compared with low Foxp3 expression (Miyara et al., 2009).
On the other hand, Foxp3- T cells, termed Tr1 and Th3, may have suppressive properties.
Thus, identification of Foxp3+ cells is not synonymous with identification of 
immunosuppressive T cells, but no other single marker has proved to be better. The crucial 
importance of this transcription factor for immunosuppressive function is demonstrated 
clinically by the fact that mutations in the FOXP3 gene results in a multiorganic 
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inflammatory syndrome (Wildin et al., 2002; Walunas et al., 1996). For further discussion on 
Tregs see section 2.3.5.
CTLA-4. CTLA-4 (CD152) may be expressed on the plasma membrane of T cells and 
is a structural homologue of the co-stimulatory molecule CD28. CTLA-4 binds to CD80 and 
CD86 located on APCs in competition with CD28 and prevents CD28-CD80/CD86-induced 
T cell activation (Walunas et al., 1996; Krummel and Allison, 1996). CTLA-4-CD80/CD86 
interaction transduces suppressive signals to the T cell leading to cell cycle arrest and aborted 
IL-2 secretion (Krummel and Allison, 1996). Mice lacking CTLA-4 display immune-
mediated multiorgan failure (Tivol et al., 1995). CTLA-4 may be expressed on effector T 
cells, but concomitant expression on Foxp3+ cells is highly suggestive of active Tregs
(Sakaguchi et al., 2010; Malek and Castro, 2010).
CD25. CD25 is the 	 of the high-affinity IL-2 receptor complex located on the 
plasma membrane. It is transiently expressed upon activation of all T cells, but constitutive 
and high expression marks Tregs (Malek and Castro, 2010). As proposed by Sakaguchi, 
concomitant high expression of CD25 and Foxp3 is confined to Tregs (Sakaguchi et al., 
2010). The suppressive significance of signaling through the IL-2 receptor is demonstrated
both by deletion of IL-2 and by deletion of CD25 in mice, which both lead to lethal 
autoimmune syndromes (Malek and Castro, 2010). CD25 may also be expressed by blood 
monocytes or activated macrophages (Smith et al., 2005).
Ly-6G. Ly-6G is surface molecule used as a restricted marker for murine granulocytes
(Lai et al., 1998).
Ki-67. Ki-67 is a nuclear protein always present during all phases of cell cycle but 
never present in resting cells (Scholzen and Gerdes, 2000). It is therefore considered an 
excellent marker for proliferating cells. Although Ki-67 appears to be required for cellular 
proliferation, its molecular function is still unknown (Scholzen and Gerdes, 2000).
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5.5 Bacteriological assays
5.5.1 Bacteriological cultivation
Bacterial cultivation assays were performed (papers III and IV) in relation to the microbiota 
depletion treatment. The assays were performed at Peter Gaustad’s laboratory at the Institute 
for Microbiology.
First, feces were assessed for a numerical estimate of cultivable bacteria. To minimize 
the risk of contamination, mice were let to defecate directly into clean Eppendorf tubes
prefilled with ice cold sterile phosphate buffered saline (PBS), and the wet weight of the 
pellets were calculated. Dry weight would have been more valid for estimation of fecal mass, 
but removing water from the pellets would have killed most of the bacteria present.
The selection of agar plates was made to detect all major groups of cultivable bacteria. 
Colonies detected by this assay were identified down to genus or family level based on the 
selective media they were collected from, colony morphology, and Gram staining. Most of the 
intestinal microbiota is as yet not cultivable ex vivo as these microbes are fastidious and often 
highly susceptible to oxygen toxicity (Duncan et al., 2007; Peterson et al., 2008). The 
cultivation assay was not performed in order to give an exact number or identification of the 
intestinal microbes, but to provide a reference that later could be used in the evaluation of the 
effect of the antibiotic treatment.
After antibiotic treatment fecal pellets were collected and weighted in the same 
manner as above. However, to optimize the sensitivity of the assay we plated all fecal 
suspensions on agar plates nutritionally sufficient for all cultivable intestinal aerobic and 
anaerobic bacteria and for yeasts. The incubation time was extended to 48 hours for the 
aerobic agar plates and 72 hours for the anaerobic agar plates. As the median wet weight of 
the fecal pellets collected was 46 mg (ranging from 17 to 120 mg) and 1/10 of the mass was
plated on each agar plate, we reasoned that viable bacteria present in the fecal pellets at a 
concentration lower than 1 cfu/mg would remain undetected. Theoretically the cultivation 
assay may have been affected by remnant antibiotics in the fecal samples, but we judged this
unlikely because of dilution of the inoculated antibiotics, first in the gut fluids and feces and 
then in the PBS of the fecal sample.
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5.5.2 Molecular biological microbial analyses
As mentioned above only a fraction of the intestinal microbiota is generally accessible for ex 
vivo cultivation. Over the last two decades new culture independent technologies have been 
developed to explore the microbial communities of the gut (Peterson et al., 2008). Until 
recently these technologies have been based on 16S rRNA gene analysis of bacteria. 16S 
rRNA is a subunit of the rRNA of all bacteria. As the ribosome is essential for the life of the 
bacteria, the 16S rRNA gene is generally highly conserved making it a target for evolutionary 
and taxonomic studies (Clarridge, III, 2004). Also, the 16S rRNA gene contains hypervariable 
regions making it useful for identifying bacteria down to strain level by comparing sequences 
with gene databases (Peterson et al., 2008). In paper III and IV we applied two different 16S 
rRNA gene analyses.
In paper III primers were designed for the conserved regions flanking variable 
regions V2 and V6 of the 16S rRNA gene. Fecal samples were analyzed by quantitative 
polymerase chain reaction (qPCR) in order to quantify the bacterial load in the fecal pellets
after antibiotic treatment. Two issues regarding this assay deserve a brief discussion. First, the 
qPCR assay would amplify and detect all target genes present in the samples regardless of the 
viability of the bacteria. Thus, the amount of 16S rRNA gene present in the sample does not 
directly correlate to the number of live bacteria present in the gut. Second, by comparing the 
gut bacterial DNA load of mice between different mice the mass of detected bacterial DNA 
had to be normalized to a fixed measure. The fecal samples were weighted, but as the water 
content of the pellets may vary the wet weight was not considered to be an adequate measure. 
As described in paper III we normalized the bacterial DNA to genomic mouse DNA. This 
analysis is based on the assumption that all mice have the same mass of epithelial cells in their 
gut and shed intestinal epithelium at the same rate. The added advantage of comparing DNA
(bacterial) with DNA (murine) is identical purification procedures, molecular stability etc.,
thus reducing the influence of differences in yield and quality of different samples.
In paper IV the composition of the intestinal microbiota of pIgR KO mice and wt 
counterparts was assessed by phylogenetic microarray. Snap frozen fecal pellets and cecal 
samples were shipped to Hauke Smidt’s laboratory in Wageningen, the Netherlands where the
processing of the samples, microarray and bioinformatics were performed. The principle of 
the technology is to extract DNA from the samples, amplify the bacterial 16S rRNA DNA by 
PCR, and detect target sequences by nucleotide probes printed on a glass slide. The
technology, which is called the mouse intestinal tract chip (MITChip), is newly designed and 
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as of today not yet published, but is based on the technology of a human intestinal tract chip
(HITChip) (Rajilic-Stojanovic et al., 2009). The MITChip/HITChip technology offers 
excellent reproducibility and specificity, and with a resolution comparable to FISH and 
superior to DGGE (Rajilic-Stojanovic et al., 2009). The MITChip/HITChip is a semi-
quantitative analysis that offers information about the abundance of the target sequence. The 
phylogenetic microarray provides accurate information of the taxonomic composition of the 
intestinal microbiota (“who is there?”) but does not offer any information on functional 
disparities between different samples (“what are they doing?”). As bacteria extensively 
transfer genes horizontally one cannot infer that differences in 16S rRNA gene analyses 
implies functional differences of the microbial community as a whole. Recently published 
reports on sequencing the combined genome of the intestinal microbial community
(“microbiome”) may provide such information (Nelson et al., 2010; Qin et al., 2010).
5.6 Statistics
As in all experimental biomedical research the numbers of individuals (persons or animals) or 
samples, termed the experimental units, examined in this thesis are relatively small. Still,
proper statistical handling of the data is crucial to draw scientific conclusions. The applied 
statistical methods are described in the individual papers, but a few key issues regarding the 
choice of the methods are discussed here.
As the experimental units are relatively few and consequently the sample sizes of each 
experimental group are small, a decision has to be made whether to apply parametric 
statistical tests or non-parametric tests. If all assumptions for parametric tests are met,
parametric tests offer greater ability to detect a true significant difference between groups
(Lamb et al., 2008). The main assumption for using parametric tests is a normal distribution 
of data within each sample group. There is no clear definition of when to regard a data set 
normally distributed. Formal statistical tests for normality exist, but these are considered 
unnecessary (Lamb et al., 2008). Based on literature and consultations with biostatisticians we 
considered data set normally distributed if the visual impression of symmetry around the 
mean in columnar scatter plots was evident; and if mean and median values were 
approximately equal; and if the nature of data indicated normality. No minimal number of 
experimental units per experimental group was set as a requirement for assuming normality.
Other assumptions on which the applied statistical tests are based are: that the experimental 
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units are either randomly selected from a population or randomly allocated to the 
experimental group; that the experimental units are independent of each other both within 
groups and across the groups; and that the variances between groups are relatively equal
(Lamb et al., 2008). Except for the procedure of the stabling of mice which could be 
questioned with regard to independency (see section 5.2.5), these assumptions were met for 
all our analyses where parametric statistics where applied.
A disparity exists between papers I and II in terms of applied statistical method 
considering that assessments performed on partially the same specimens. When designing the 
project resulting in papers I and II we regarded the sample sizes too small for parametric tests 
and we therefore initially performed non-parametric tests. However, when analyzing data for 
paper II we considered the possibility of adjusting the cell density counts for inflammation 
score. We discussed this with a statistician (co-author J.M.G), and the data were judged to be 
eligible for parametric statistics.
Comparisons between two independent groups were analyzed with independent (a.k.a 
unpaired) tests (e.g. Student t test, Mann-Whitney). When comparing more than two groups
these were analyzed with analysis of variances (ANOVA) rather than multiple t tests. The 
ANOVA tests reduce the chances of statistically significant results to erroneously occur by 
chance (type I error). Relevant post-tests were performed with Bonferroni adjustment. 
ANOVA tests require assumptions of normality to be met.
In paper I and II we performed multiple tests and not ANOVA. The choice of test
was discussed with a statistician and considered valid because a number of null hypotheses
were defined and decided to be tested prior to the acquisition of data, and because not all 
comparisons between various groups were considered relevant (e.g. adult colon vs. pediatric 
ileum). 
All tests were performed as two-tailed tests and the level of significance (	-(		
consistently set to the conventional 0.05. 
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6 DISCUSSION
Discussions of the isolated results of the individual papers are provided in the respective 
manuscripts. This chapter provides an integrated discussion of the results in relation to the 
aims of the thesis.
This thesis aimed at providing new information on mucosal immunopathogenic 
mechanisms in IBD. Papers I and II present novel observations on the distribution of 
macrophages and Tregs cells in the mucosa of recent onset pediatric IBD patients compared 
with recent onset adult IBD patients. The study design founding the basis for these papers is 
original, as at the time of diagnosis biological material from untreated patients were collected. 
This provided insight into the early pathogenesis of IBD. Most investigations of biologic 
material from IBD patients have been based on collections from patients with long-standing
disease and concurrently varying medication. To our knowledge the two papers included here 
are the first to have investigated mucosal specimens from exclusively untreated pediatric 
patients at the time of diagnosis and having compared them with specimens from untreated 
adult patients at the time of diagnosis.
Papers I and II report on differential distribution of macrophages and Tregs, both 
important players in intestinal mucosal homeostasis (Hooper and Macpherson, 2010). We 
suggest that these differences may contribute to phenotypic differences in pediatric and adult 
onset IBD. This hypothesis is based on the assumption that there is no qualitative difference 
in the function of these cell types in pediatric versus adult patients. Regarding macrophages,
researchers have proposed that CD is the result of impaired macrophage function (Casanova 
and Abel, 2009). Dysfunction of Tregs has not been linked to development of IBD, but the 
increasing knowledge of plasticity between Tregs and Th17 effector cells makes it difficult to 
assess the exact role of Foxp3+ Tregs in the etiology and pathogenesis of IBD (Sakaguchi et 
al., 2010).
Papers I and II describe that the pediatric control patients have fewer macrophages in 
their colon and that the pediatric CD patients have more Tregs in their ileum compared with 
adults, but no mechanistic explanations are provided. As we have demonstrated in the 
included Papers IV and V and consistent with the current literature, nearly all experimental 
IBD animal models depend on the presence of intestinal microbes (Uhlig and Powrie, 2009).
Furthermore, both experimental and human IBD are associated with alterations in the 
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composition of the intestinal microbiota (Sartor, 2008). Is it possible that the altered 
distribution of immune cells described in Papers I and II has been caused by or is associated 
with microbial perturbations? Few investigations have been performed on the microbiota in 
pediatric IBD and none have identified alterations specific to the pediatric segment (Conte et 
al., 2006; Schwiertz et al., 2010). However, as recent animal studies have identified key 
phylotypes responsible for the induction of Tregs (see section 2.3.5), the hypothesis that the 
differential distribution of macrophages and Tregs is instigated by pediatric-specific microbes, 
which ultimately may cause the pediatric-specific IBD phenotypes, deserves to be explored.
The methodology of papers I and II did not allow functional assessments of the role 
of macrophages and Tregs in the IBD lesions. It is well documented that activated (CD40+)
macrophages contribute to drive inflammation (Mosser and Edwards, 2008; Smith et al., 
2010). It is therefore likely that the increased density of activated macrophages leads to 
increased inflammatory potential in the IBD lesion. Regarding Tregs, it may seem 
counterintuitive that there are many studies along with ours that report that Tregs are
generally increased in numbers in all kinds of inflammatory lesions. Our analysis of the 
distribution of Tregs in the intestinal mucosa indicated that there are spatial differences in the 
distribution of Tregs regardless of the inflammatory status of the examined biopsy. 
Experimental studies on the inflammatory potential in lesions with or without Tregs are not 
possible to perform in humans. However, humans with mutations in FOXP3 (IPEX) have 
IBD-like enteropathy, and  experimental animal studies have demonstrated that Tregs are able 
to both prevent colitis and attenuate established disease (Fantini et al., 2006; Mottet et al., 
2003). Thus, the functional role of the cell types studied in papers I and II should not be 
controversial. The applied immunohistochemistry methods provide a snapshot of real life 
distribution of key players in mucosal homeostasis.
Papers III-IV focus on the roles of colonic epithelial cells and the transport of SIg in 
laboratory animal models. These are essential components of mucosal homeostasis along with 
macrophages and Tregs. The homeostatic function of IEC, IgA, macrophages, and Tregs all 
pivot around a few key cytokines such as TGF-, IL-10, TSLP and RA. Recently, 
experimental studies have presented evidence for Tregs’ promotion of IgA production, a.k.a 
as a Treg-IgA axis (Feng and Elson, 2011).
The second aim of this thesis was to elucidate interactions between secretory 
immunoglobulins and intestinal epithelial cell function on one hand and the intestinal 
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microbiota on the other. Paper IV shows how lack of SIg makes mice more susceptible to 
experimental colitis and that this is associated with alterations of the composition of the 
intestinal microbiota and of the colonic IEC gene expression profile. These results are
consistent with previously published data in mice (Murthy et al., 2006). However, as 
previously mentioned, data recorded in mice cannot automatically be extrapolated to humans. 
There are well known differences in the IgA system between mice and men (reviewed by 
Gibbons and Spencer (Gibbons and Spencer, 2011). In humans, no mutation resulting in 
aborted function of pIgR is known. From an evolutionary point of view, this may indicate that 
lack of pIgR is incompatible with life in humans as opposed to in mice. Alternatively, a 
defective pIgR may have little consequence in healthy humans living in a clean environment 
and therefore not have been identified. There are known single nucleotide polymorphisms in 
the human PIGR gene (2007). Some of these correlate with IgA nephropathy and with 
Epstein-Barr virus diseases, but none have been shown to correlate with IBD or other 
intestinal diseases.
On the other hand, selective IgA deficiency is well described in humans with a 
prevalence of 1:200 to 1:1000 in western societies. IgA deficiency leaves most of the affected 
persons asymptomatic, but it is still associated with increased incidence of IBD (Cunningham-
Rundles, 2001). The reason for the mild disease phenotype in selective IgA deficiency is not 
established, but one hypothesis suggest that increased levels of SIgM could compensate for 
the lack of SIgA (Cunningham-Rundles, 2001). However, also patients with X-linked 
agammaglobulinemia, which lack all classes of immunoglobulins, rarely present with 
gastrointestinal disorders (Agarwal and Mayer, 2009). This suggests that isolated loss of 
immunoglobulins in humans is not critical to gut homeostasis, and consequently that there is 
redundancy to humoral immunity for maintenance of mucosal homeostasis. In humoral 
immunodeficencies such as common variable immunodeficiency, it is believed that intestinal 
inflammation is dependent on concurrent impairment of T cell function (Agarwal and Mayer, 
2009). Also, mice gut homeostasis is dependent on T cell function (Gibbons and Spencer, 
2011). One study has demonstrated the importance of Tregs for mediating OVA specific 
tolerance in pIgR KO (Karlsson et al., 2010), but further reports on T cell functions in the 
pIgR KO and JH KO mouse models are lacking. 
Paper IV outlines changes in the composition of the intestinal microbiota in mice 
deficient in SIgs. As previously mentioned, several new pieces of evidence indicate how the 
intestinal microbiota is shaped by SIgA. Reports on how humoral immunodeficiency affects 
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the intestinal microbiota in humans are sparse, and to our knowledge the microbiota of these 
patients have not been assessed with modern phylogenetic tools. Such studies would be of 
great interest as they could validate the relevance of the observations in mice and help with 
identifying defined phylotypes that exploit the lack of SIgs to establish their niche.
To what extent do the results from this thesis provide information that can be 
implemented into efforts to prevent IBD or improve the care of affected patients?
Immunosuppressive therapy by enhancing Treg function based on principles of ex vivo
expansion and reinfusion is under intense research (Sakaguchi et al., 2010). The finding of
increased density of Tregs in an intestinal segment of pediatric intestines with reduced 
occurrence of CD lesions (paper II) should encourage continuation of this line of research.
Our results in the mouse models (papers III-V) confirm previous reports that colitis is 
dependent on presence of intestinal microbes, and we showed that mice with increased
susceptibility to colitis had an altered composition of the microbiota. However, since these 
mice were lacking SIgs and pIgR-mediated mucosal protection, we cannot determine whether 
enhanced susceptibility to DSS-induced colitis was due to altered microbiota or altered 
handling of the present microbes. Key phylotypes that potentially cause IBD have yet to be 
identified. The idea of modulating the intestinal microbiota to treat IBD has been pursued. 
Probiotics have shown promising results in ulcerative colitis, but larger clinical trials are still 
lacking. Recent reports on specific phylotypes responsible for Treg induction in the gut of 
mice may give a clue to key species that a probiotic concoction should contain (Atarashi et 
al., 2011). Allogenic fecal transplantation, which is becoming established therapy for resistant
C. difficile infections, has been tested in  IBD patients with good results (Khoruts and 
Sadowsky, 2011). Recent data in an experimental mouse model demonstrated that colitogenic 
bacterial strains can be transferred vertically (mother to pup) and horizontally (between litter 
mates) in mice (Garrett et al., 2007; Garrett et al., 2010). Fecal transplantation from a healthy 
to an affected individual is the therapeutic analogue to those observations and should be 
explored more thoroughly despite esthetical concerns. Our results along with other 
experimental data on the interaction between IgA and intestinal microbiota (Peterson et al., 
2007; Suzuki et al., 2004) suggest that IBD patients with impaired humoral immunity should
in particular benefit from restoration of a healthy gut microbiota.
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7 CONCLUSIONS
Intensive research over the past few decades has demonstrated that IBD is associated with 
disrupted homeostasis in the intestinal mucosa with alterations in both host immunity and in 
the intestinal microbiota. This thesis provides the following new information to the ever
increasing knowledge on disrupted intestinal mucosal homeostasis:
 Histologically normal colonic mucosa has a higher density of macrophages in children 
than in adults. 
 Activated mucosal macrophages are increased in untreated pediatric IBD.
 The majority of CD25+ cells in intestinal mucosa are macrophages.
 Densities of mucosal Foxp3+ Tregs and CD25+ cells (activated macrophages) are 
elevated in both pediatric and adult ileal CD regardless of histological inflammation.
 Cultivatable intestinal microbiota can be depleted by gavaging antibiotics, and the 
biological effect of this treatment phenocopies physiological characteristics of germ-
free mice.
 Mice lacking SIg because of abrogated transport of pIg have altered composition of
the intestinal microbiota, and this is associated with increased susceptibility to 
experimental colitis and differential gene expression profile of colonic IECs.
 Absence of pIgR protects B cell-deficient mice from microbiota-dependent colitis.
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ERRATUM
In paper IV "Altered mucosal homeostasis in mice lacking secretory antibodies”, page 5,
bottom paragraph, the stated number of genes differentially expressed between conventional 
pIgR KO mice and pIgR KO that have been gavaged antibiotics is wrong:
“Strikingly, the number of differentially expressed genes between pIgR KO and wt 
mice was reduced to 27 when the conventional microbiota was suppressed by 
antibiotic treatment (Fig. 1A). We also compared differential gene expression between 
antibiotic-gavaged pIgR KO and pIgR KO with a conventional intestinal microbiota 
and found 208 genes more than 2-fold differentially expressed.”
In paper IV’s figure 1A, page 45, the number for the comparison between antibiotic-gavaged
pIgR KO and pIgR KO with a conventional intestinal microbiota is given as 296. There is 
therefore a discrepancy between the results section, page 5, and the figure 1A that is referred 
to in the results section. The number in the figure is correct. 
The second last sentence on page 5 should read:
“We also compared differential gene expression between antibiotic-gavaged pIgR KO 
and pIgR KO with a conventional intestinal microbiota and found 296 genes more 
than 2-fold differentially expressed.”
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Abstract
Background: Inappropriate cross talk between mammals and their gut microbiota may trigger intestinal inflammation and
drive extra-intestinal immune-mediated diseases. Epithelial cells constitute the interface between gut microbiota and host
tissue, and may regulate host responses to commensal enteric bacteria. Gnotobiotic animals represent a powerful approach
to study bacterial-host interaction but are not readily accessible to the wide scientific community. We aimed at refining a
protocol that in a robust manner would deplete the cultivable intestinal microbiota of conventionally raised mice and that
would prove to have significant biologic validity.
Methodology/Principal Findings: Previously published protocols for depleting mice of their intestinal microbiota by
administering broad-spectrum antibiotics in drinking water were difficult to reproduce. We show that twice daily delivery of
antibiotics by gavage depleted mice of their cultivable fecal microbiota and reduced the fecal bacterial DNA load by 400
fold while ensuring the animals’ health. Mice subjected to the protocol for 17 days displayed enlarged ceca, reduced Peyer’s
patches and small spleens. Antibiotic treatment significantly reduced the expression of antimicrobial factors to a level
similar to that of germ-free mice and altered the expression of 517 genes in total in the colonic epithelium. Genes involved
in cell cycle were significantly altered concomitant with reduced epithelial proliferative activity in situ assessed by Ki-67
expression, suggesting that commensal microbiota drives cellular proliferation in colonic epithelium.
Conclusion:We present a robust protocol for depleting conventionally raised mice of their cultivatable intestinal microbiota
with antibiotics by gavage and show that the biological effect of this depletion phenocopies physiological characteristics of
germ-free mice.
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Introduction
The human gut harbors a microbiological community of 1014
bacteria consisting of more than a 1000 species whose collective
genome (‘‘microbiome’’) outnumbers the human genome by more
than a 100 fold[1,2]. The cross talk between the host and its
intestinal microbiota is of obvious significance for the function of the
intestines[3], and has also been shown to be important for immune-
mediated diseases with extra-intestinal manifestations such as in
allergy and asthma[4]. More recently the influence of the intestinal
microbiota in experimental models for both type 1 diabetes,
obesity, and multiple sclerosis has been demonstrated[5–7].
Microbe-associated molecular patterns (MAMPs) use an array of
germ-line encoded pattern recognition receptors (PRRs) to
activate signaling pathways in host cells [8,9]. Importantly,
signaling via these receptors drive host inflammatory responses to
microbes[10–12], but can also mediate mucosal homeostasis and
integrity when the microbe or microbial product is delivered via
the intestinal lumen to the intact epithelium[8,9]. Functional
assessments of the intestinal microbiota’s impact on the host is
thus of great interest.
The intestinal epithelium, consisting of a single cell layer,
composes the barrier between the host sterile environment and the
bacteria-rich intestinal lumen. Having only a partially bacteria-
free mucus layer as a mechanical shield[13], the intestinal
epithelial cells (IECs) are in direct contact with the highly diverse
microbiota[14,15]. The enterocytes express a wide range of PRRs
whose functions and engagement by MAMPs are essential for the
homeostasis of the intestinal mucosa[8,9]. The other way around,
IECs are shown to modulate the microbiota through the secretion
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of antimicrobial peptides[16] (and reviewed in ref[15]) and by
facilitating the transport of secretory IgA[17,18]. Even though the
close and mutual relationship between the intestinal microbiota
and the IECs is demonstrated, very little knowledge exists about
how the full gene expression repertoire in the colonic IECs is
regulated by the presence of a complete conventional microbiota.
Germ-free animals bred in sterile environment may potentially
be used for such comparative studies. However, establishing and
running germ-free facilities is expensive and requires special
expertise and infra-structure. Compared with animals living in a
conventional microbiological environment, germ-free animals
display an immature and underdeveloped lymphoid system[19].
A generally accessible alternative to using germ-free animals for
studying host-microbe interaction in vivo is to deplete animals of
their intestinal microbiota by using a combination of broad
spectrum antibiotics administered per os. In a hallmark paper,
Rakoff-Nahoum and colleagues delivered broad-spectrum antibi-
otics in the drinking water to demonstrate that intestinal MAMPs
signaling via Toll-like receptors (TLRs) supported gut homeosta-
sis[20]. However, many have found it difficult to reproduce this
protocol, and researchers who have succeeded in making mice
drink the antibiotics ad libitum have experienced increased baseline
morbidity and mortality among some strains and genotypes of
mice subjected to this protocol (W. Garrett, personal communi-
cation). Importantly, several published papers that report to have
applied this intestinal microbiota depletion protocol describe
incomplete depletion of the cultivable bacteria[21–23].
In order to compare the gene expression profiles of colonic IECs
in the presence and absence of a complete intestinal microbiota,
we determined to refine a protocol that would deplete mice of their
cultivable intestinal microbiota in a predictable and reproducible
manner while ensuring the health of the animals. We demonstrate
that applying this refined protocol we obtain mice which resemble
germ-free mice in terms of hypoplastic lymphoid tissue. Impor-
tantly, antibiotic-gavaged mice have significantly altered gene
expression profiles of colonic IECs resembling those of germ-free
mice and affecting a wide range of pathways.
Results
Delivering antibiotics by gavage ensures health of the
mice
We attempted to deplete mice of their intestinal microbiota by
providing ampicillin, vancomycin, neomycin, and metronidazol ad
libitum in drinking water according to the previously published
protocol[20]. However, BALB/c mice consistently refrained from
drinking the concoction, presumably due to the foul taste of
metronidazol (Figure 1A). Respecting the ethical standards of our
animal facility and the humane end point of.20% loss of baseline
body weight, we had to euthanize all mice receiving the full
antibiotic combination (Figure 1B). Adding low caloric aspartame-
based sweetener with the concoction in an attempt to mask the
taste of the antibiotics also failed (Figure 1C, D). C57BL/6 mice
displayed the same unwillingness as BALB/c mice to drink the
antibiotic concoction provided ad libitum (data not shown).
To ensure a safe and stable delivery of the antibiotic concoction
to every mouse subjected to the protocol we administered it by
gavage every 12 hours. Due to occasional overgrowth of Candida
spp. in pilot experiments (data not shown), we initiated our
protocol with 3 days treatment of gavaging the antifungal
substance amphotericin-B (1 mg/kg bodyweight (BW)) attempting
to suppress fungal growth prior to starting the antibacterial
treatment (Figure 2A). From day 3, ampicillin 1 mg/ml was added
to drinking water and mice were gavaged every 12 hours with the
antibiotic concoction consisting of vancomycin 50 mg/kg BW,
neomycin 100 mg/kg BW, metronidazol 100 mg/kg BW, and
amphotericin-B 1 mg/kg BW.
Gavaging mice did not inflict detectable distress or pain. Six
weeks old mice given water gavage of a volume and frequency
identical to the mice receiving the antibiotic concoction displayed
unaltered weight gain compared with mice receiving water ad
libitum only (Figure 2B). Some mice gavaged with antibiotic
concoction experienced a transient weight loss on day 4–5 after
introduction of the antibacterial therapy (Figure 2B). This
transient weight loss we believe was caused by mice adjusting to
ampicillin in drinking water rather than the gavaged concoction as
we observed that mice receiving ampicillin in drinking water as
only therapy had the same transient drop in body weight
(Figure 1B). Within a week mice receiving the full antibiotic
therapy had regained their weight compared with their untreated
peers and appeared healthy.
Antibiotic therapy by gavage effectively depletes
cultivable microbiota and reduces fecal bacterial DNA
load
Fecal bacteria of untreated mice were enumerated by
cultivations of serial dilutions of resuspended fecal pellets on
differential media (Figure 3A). Validation of successful depletion
after the antibiotic gavage treatment was performed by cultivation
of fecal pellets collected and handled aseptically on day 13 and 24.
Due to limitations in the quantity of fresh fecal pellets that could
be collected, the detection limit for this assay was set to 1 cfu/mg
feces and mice with , 1cfu/mg feces were defined as successfully
depleted. Only animals successfully depleted by this criterion were
included in further characterization of antibiotic treated mice. At
day 13, 86% of the mice subjected to the protocol displayed
successful depletion of their cultivable aerobic and anaerobic fecal
microbiota (Figure 3B). At day 24, the corresponding fraction was
74%. Thus, in depleted mice (,1 cfu/mg feces), we obtained a
minimum of 100-fold reduction of cultivable aerobic Gram
negative rods and 106-fold reduction of cultivable aerobic Gram
positive cocci as well as cultivable anaerobic fecal bacteria. A
similar depletion efficacy was obtained in C57BL/6 mice as in
BALB/c mice (data not shown).
As the majority of the intestinal microbiota is not cultivable[1]
we estimated the load of bacterial DNA in feces by 16S rRNA
gene quantitative polymerase chain reaction (qPCR). DNA from
fecal pellets was isolated and the V2 and the V6 region of bacterial
16S rRNA genes amplified with degenerate primers targeted to
conserved flanking sequences. Due to shedding of epithelial cells,
feces contain host DNA. Taking advantage of this we quantified
mouse DNA by qPCR and used this value to normalize the
amount of bacterial 16S DNA present (Figure 3C). We found that
all mice subjected to the depletion protocol had significantly
reduced copy number of 16S rRNA genes in their feces: the level
of bacterial DNA was similar in all samples of antibiotic treated
mice and, on average, more than 400 fold less than the level in
untreated mice demonstrating the effect of the microbiota
depletion protocol.
Depletion of gut microbiota produces a macroscopically
germ free-like phenotype
Mice born and raised in a germ-free environment possess
numerous characteristics distinguishing them from mice living
in a conventional microbiological environment. Macroscopi-
cally, germ-free mice display hypoplastic secondary lymphoid
organs, enlarged ceca, and reduced epithelial cell turnover[19].
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Mice verified to be successfully depleted after treatment with
the antibiotic concoction by gavage for 17 days displayed
significantly fewer Peyer’s patches, smaller spleens and enlarged
ceca (Figure 4A–D), macroscopically phenocopying germ-free
mice.
Immuno luorescent staining of sections from the colon of these
same animals demonstrated that they had acquired a reduced
epithelial regenerative activity in terms of fewer Ki67+ cells than
what was observed in mice with an intact intestinal microbiota
(Figure 4E, F).
Depletion of gut microbiota alters gene expression in
colonic epithelium illustrative of germ-free mice
As we observed that the refined depletion protocol affected
such a basic function of IECs as the regenerative activity, we
wanted to study how the intestinal microbiota affected IECs
globally by performing gene expression profile analysis on
isolated colonic IECs of mice successfully depleted by the refined
microbiota depletion protocol compared with that of sham
treated control mice. We identified a total of 517 differentially
expressed genes. However, many of these genes only showed a
small alteration in expression level between antibiotic treated and
control animals.
Focusing on genes with at least a 2-fold altered expression 36
genes were higher expressed and 70 genes showed reduced
expression upon antibiotic treatment (Figure 5A). Gene ontology
analysis revealed that expression of genes related to cell cycle and
lipid biosynthesis were the most affected of the antibiotic treatment
but also inflammatory response genes were significantly altered
(Figure 5B). Strikingly, 5 of the 7 genes that had more than 4-fold
reduced expression in antibiotic treated mice encode known
antimicrobial factors[24–29] (Table 1).
To validate the gene expression profile and its relevance to
germ-free mice we performed quantitative reverse transcriptase
(qRT)-PCR on all nine genes that showed more than 4-fold
differential expression by microarray analysis (Table 1). For all
nine genes tested, the qRT-PCR confirmed the differential
expression between antibiotic-gavged and sham-treated mice
discovered in the array (Figure 6). In all cases, the fold difference
between the two groups was greater when gene expression was
determined by qRT-PCR than by micro array. Moreover,
differential gene expression of colonic IEC from germ-free mice
versus conventional age- and gender matched controls showed
similar pattern as the antibiotic-gavaged versus sham treated mice.
For most of the genes the antibiotic treated and germ-free mice
showed similar expression levels (Figure 6).
Figure 1. Mice refrain from drinking antibiotics ad libitum. Experiments attempting to administer mice ampicillin 1 g/l (A), vancomycin
500 mg/ml (V), neomycin 1 g/l (N), and metronidazol 1 g/l (M) in drinking water ad libitum. Water indicates mice receiving regular drinking water.
Skulls represent euthanized animals. Stapled lines indicate humane endpoint of 20% loss of body weight. Treatment groups presented as mean 6
SD. Deceased mice excluded from subsequent time points after death. (A) Daily fluid consumption estimated by daily weighting of flasks and (B)
bodyweight presented as percent of baseline ( = Day 0) for mice receiving the full AVNM concoction (red) in drinking water as well as for mice
receiving the individual antibiotics as single solutions in drinking water, n = 5 for all groups. (C) Daily fluid consumption and (D) bodyweight
presented as percent of baseline ( =Day 0) attempting to mask the foul taste of the antibiotic concoction AVNM in drinking water by adding the
aspartame-based sweetener CanderelH 1.5% weight/volume, n= 6 for AVNM + CanderelH 1.5% group, n = 4 for water control group.
doi:10.1371/journal.pone.0017996.g001
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Discussion
Recently, there has been an increased understanding of the
importance of intestinal microbiota for human physiology,
evidenced by large endeavors such as the MetaHIT project[2]
and the Human Microbiome Project[30]. However, simple
protocols for manipulation of intestinal microbiota in experimental
animals are also needed. Thus, the seemingly simple method of
depleting mice of their cultivatable microbiota by adding a
concoction of antibiotics in drinking water has gained a lot of
Figure 2. Protocol for administering antibiotics by gavage ensures mice health. (A) Sketch of protocol for gavage administration of
vancomycin 50 mg/kg (V), neomycin 100 mg/kg (N), metronidazol 100 mg/kg (M), and amphotericin-B 1 mg/kg (Amf-B) every 12 hours with
ampicillin 1 g/l ad libitum in drinking water (A). (B) Body weight, presented as percent of base line ( =Day 0), of mice successfully depleted of
cultivable fecal microbiota by gavage (VNMAmf-B+A) or gavaged with water in equivalent volume and frequency (Sham). Control mice received
water ad libitum only
doi:10.1371/journal.pone.0017996.g002
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attention, but also caused a lot of frustration among immunolo-
gists. Although some labs have successfully used the ad libitum
protocol to obtain valuable data, it appears that it is not applicable
to all mouse strains or genotypes and that it is affected by the
general conditions in the vivarium. Here we have presented and
validated an alternative method which deliver the antibiotics in a
safe and predictable manner without inflicting any morbidity on
the animals. Furthermore, we demonstrated that mice subjected to
this depletion protocol acquire a germ free-like phenotype.
Our protocol for depletion of intestinal microbiota is based on
the same composition of antibacterial agents as others have
applied for ad libitum administration in drinking water. Ampicillin,
vancomycin, neomycin and metronidazol offer in combination
bactericidal activity against the full spectrum of bacteria and,
notably, dual activity against both Gram positive (ampicillin and
vancomycin) and Gram negative (ampicillin and neomycin)
aerobic and facultative strains, which is potentially important for
preventing antibiotic resistance [31]. We therefore used this
combination of antibiotics and overcame the delivery problems by
administering the antibiotics by gavage twice daily which the mice
tolerated well.
In mice treated with the gavage protocol for 17 days we
observed a reduction in the bacterial DNA load that was
substantial though numerically not as great as the reduction
observed in cultivation assays. This may reflect that the 16S DNA
qPCR detect DNA from dead as well as viable bacteria. Also, a
recent report demonstrated that bacterial DNA in the animal
chow contributes to the 16S DNA load in fecal pellets[32].
However, the fact that the few fecal samples in our assays that
contained cultivable bacteria did not distinguish themselves in
terms of higher 16S DNA load than the successfully depleted mice
(not shown) indicates that the qPCR assay is a more crude analysis.
Fecal pellets were used for evaluating the efficacy of the
microbiota depletion protocol. Microbes that preferentially adhere
to the mucosa of the mice are also affected by antibiotics[32] but
would not be thoroughly assessed by analysis of fecal pellets. Even
though the fecal pellets were devoid of cultivable bacteria and had
greatly reduced amount of bacterial DNA we acknowledge that
the intestines of the mice likely harbor residual bacteria and should
not be regarded as sterile, as in true germ-free mice. However,
collecting fecal pellets is non-invasive and allows for longitudinal
studies. Contrary to this, collecting intestinal tissue from mice to
confirm depletion of adherent bacteria would not be compatible
with having the same mice entering functional experiments.
Applying the gavage antibiotic depletion protocol had a profound
effect on the phenotype of the mice as they developed several
characteristics typical of germ-free mice. The reduced spleen,
number of Peyer’s patches, the enlarged ceca, and reduced
epithelial proliferative activity in our treated mice is also observed
in germ-free mice[19]. This suggests that these features are typical
of under-stimulation by commensals and that they are reversible
effects rather than a consequence of growing up germ free.
Furthermore, both mucosal and systemic secondary lymphoid
organs were affected by commensal depletion.
We assessed the impact of the intestinal microbiota on the
colonic IEC’s gene expression profile, which revealed that more
than 500 genes were differentially expressed as a consequence of
the antibiotic by gavage treatment. A number of genes related to
cell cycle were differentially regulated between untreated and
antibiotic treated mice, suggesting that the commensal microbiota
regulate epithelial proliferation in the colon. Furthermore,
pathways regulating lipid biosynthesis, specifically production of
arachidonic acid, appeared to be affected by the commensal
microbiota. This was due to reduced expression of several small
secreted phospholipases from the phospholipase A2 family after
antibiotic treatment. Recent reports suggest that these secreted
phosphoslipases are not primarily involved in arachidonic acid
production. Although they have enzymatic activity, they show no
substrate specificity for arachidonic acid release[26,33]. Further-
more, secreted phospholipases have been shown to have
antimicrobial activity[26,34].
In colonic IEC from germ free mice and matched conventional
mice we determined the expression level of nine genes strongly
affected by our antibiotics by gavage treatment. In eight out of
nine cases, differences between antibiotic and sham treated mice
were nearly identical to differences between germ-free and
conventional mice strongly suggesting that the altered gene
expression profile is a consequence of the highly reduced microbial
stimulation of the colonic IECs. For these eight genes we rule out
that altered gene expression due to antibiotic treatment was a
consequence of a direct pharmacologic effect of the antibiotics.
These comparisons support the validity of the antibiotic treatment
as an analogue to germ-free status in mice.
The greatest fold change was seen in genes coding for
antimicrobial factors, some of which (Ang4[24], Retnlb[25]
Reg3g[28] and Reg3b[25]) have been demonstrated to be induced
by microbial stimuli through mono-associating or conventionaliz-
ing germ-free mice or by comparing germ-free and conventionally
bred mice. Retnlb, Reg3g, and Reg3b have also previously been
shown to be down-regulated after antibiotic treatment[25,35].
These studies have been performed on samples from the small
intestines and we now complement these by demonstrating the
identical effect in the colon. We believe we are also the first to
demonstrate that in the colon high expression of the antimicrobial
factor Pla2g2a is dependent on the presence of the intestinal
microbiota, which is incongruent to previous observations in the
small intestines[24]. The reduced expression of antimicrobial
factors in IEC from mice depleted of commensal microbiota (to
levels similar to that of germ free mice) demonstrate that
continuous presence of microbial stimuli is required to maintain
normal expression level of these genes.
To our knowledge only one study has performed gene
expression profile comparison on colonic IECs from germ-free
and conventionally bread mice. In the infancy of array-based gene
expression assays Fukushima et al. compared mRNA expression
profiles of colonic IEC from germ-free mice with mice with
conventional non-pathogenic microbiota and confirmed two genes
downregulated and five genes upregulated in germ-free mice[36].
Of these seven genes four were similarly differentially expressed in
our microbiota depleted mice. This comparison lends further
support to our hypothesis that the differentially expressed genes in
Figure 3. Protocol for administering antibiotics by gavage effectively reduces intestinal bacterial contents. (A) Enumeration of
cultivable fecal bacteria (mean 6 SEM) in untreated mice. (B) Efficacy of successful depletion (,1 cfu/mg feces) of cultivable gut microbiota and
distribution of aerobe, anaerobe, and fungal overgrowth (def.: $1 cfu/mg feces) after 13 and 24 days of treatment with vancomycinm (V), neomycin
(N), metronidazol (M), and amphotericin-B (Amf-B) every 12 hours by gavage with ampicillin ad libitum in drinking water (A), n = 43. (C) Bacterial 16S
DNA load (mean 6 SD) in fecal pellets. 16S DNA determined by quantitative PCR for the V2 and V6 regions and normalized to total mouse genomic
DNA in the same pellets of mice treated 13 and 24 days with VNMAmf-B +A compared with water controls, n = 7 for water controls, 40 for 13 days,
and 35 for 24 days.
doi:10.1371/journal.pone.0017996.g003
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our antibiotic treated mice are caused by greatly reduced
microbial stimuli.
Two recent publications reported to having gavaged mice
with ampicillin, vancomycin, neomycin and metronidazol[7,32].
In line with our experiments, Hill et al. demonstrated the pitfall
of the previously reported antibiotics ad libitum protocol and
showed that gavaging mice with antibiotics once daily gave a
significant reduction in bacterial 16S DNA load and altered gut
phenotype[32]. Ochoa-Reparaz et al. demonstrated that mice
gavaged with the antibiotics tolerated that treatment better than
the ad libitum approach[7]. Our protocol applied a gavage
frequency of twice daily and we used higher antibiotic
concentrations than Hill et al. and Ochoa-Reparaz et al. Thus,
we were able to reduce the fecal 16S DNA load by 400 fold
while Hill et al. reported a 10-fold reduction. We have
furthermore validated the gavage protocol demonstrating
acquisition of a ‘‘germ free-like’’ phenotype of the subjected
mice. We believe that our assessments of the macroscopic
appearance of lymphoid organs and colonic IEC gene
expression profile provide additional knowledge on how the
intestinal microbiota affects a mammalian organism.
In conclusion, we present a generally accessible protocol for
depleting mice of their cultivable intestinal microbiota by
administering an antibiotic concoction by gavage every 12 hours.
Our protocol showed increased feasibility compared with previous
protocols, provided a predictable delivery of the antibiotics and at
the same time ensuring the health of the animals. We have verified
the depletion efficacy of our protocol both in terms of cultivable
microbes and in terms of bacterial DNA load in feces. Finally, our
protocol proved to produce a germ free-like phenotype of the
animals subjected to the protocol, suggesting it to be a valid and
accessible way to perform experiments on the host-bacteria cross
talk in mice.
Materials and Methods
Ethics statement
All use of laboratory animals was approved by the National
Animal Research Authority (Forsøksdyrutvalget) (approval IDs:
48/05, 1468, and 1734) and conducted in accordance with the
Norwegian Animal Welfare Act and the Norwegian Regulation on
Animal Experimentation. Humane endpoint was set to loss of
.20% body weight compared with the starting weight in each
experiment.
Mice
BALB/c mice were bred and kept in a conventional laboratory
animal facility at Centre for Comparative Medicine, University of
Oslo with temperatures maintained at 21oC and with 55% relative
humidity, 12 hour light and darkness cycles with 1 hour of dusk
and dawn. The mice received regular chow No. 3 (801080,
Special Diets Services, Witham, England) and water purified by
reverse osmosis and ionic exchange. Males 6–10 weeks of age were
used in experiments, age and weight matched for each individual
experiment to have an age span of maximum 2 weeks and a weight
range of maximum 620% of medians.
For reference controls in quantitative gene expression analyses 6
month old female BALB/c were obtained from the Clean Mouse
Facility (CMF), Department of Clinical Research, University of Bern.
Germ-free mice were bred and maintained in flexible film isolators
and germ-free status was routinely confirmed by aerobic and
anaerobic culture as well as DNA (sytox green; Invitrogen) and gram
staining (Harleco) of cecal contents to detect unculturable contam-
ination. Germ-free BALB/c mice were sacrificed under sterile
conditions and tissue collection was performed at the University of
Bern. Age- and gender matched conventionally kept controls were
from Centre for Comparative Medicine, University of Oslo.
Figure 4. Mice subjected to antibiotic gavage treatment alters macroscopic phenotype and epithelial proliferative activity. Numbers
of macroscopically visible Peyer’s patches (A), spleen weight (B), and cecal longitudinal cross section area (C), after 17 days of treatment with
vancomycin (V), neomycin (N), metronidazol (M), and amphotericin-B (Amf-B) every 12 hours by gavage with ampicillin ad libitum in drinking water
(A) compared to mice gavaged with water only (Sham). All VNMAmf-B+A treated mice exhibited successful depletion of cultivable intestinal
microbiota (,1 cfu/mg feces). (D) Photograph of VNMAmf-B+A and sham fed mice. Note the enlarged cecum (arrow) of the antibiotic treated mouse.
(E) Immunofluorescent staining for Ki67 (green) and DNA (Hoechst dye; blue) of cross sections of colons from VNMAmf-B+A fed mice and sham fed
mice with (F) enumeration of Ki67+ cells per crypt. In all graphs each symbol represents one animal and horizontal bars represent medians. Statistical
differences calculated by Mann-Whitney two-tailed test.
doi:10.1371/journal.pone.0017996.g004
Table 1. Genes $ 4-fold differentially expressed in colonic epithelium of untreated conventional and antibiotic treated mice.
Gene symbol Product Function[Reference] Conventional/Antibiotic treated
Ang4 Angiogenin, ribonuclease A family, member 4 AMF[24] 17.8
Pla2g2a Phospholipase A2, group IIA AMF[26,34] 14.4
Retnlb Resistin like beta AMF[25,27,40] 8.8
Pla2g4c Phospholipase A2, group IVC AA metabolism?[41] 8.6
Reg3g Regenerating islet-derived 3 gamma AMF[25,28] 7.6
Reg3b Regenerating islet-derived 3 beta AMF[25] 5.1
Gsdmc2 Gasdermin C2 Unknown[42] 4.1
… … … …
Casp14 Caspase 14 Proteinase?[43] 0.23
Cyp4b1 Cytochrome P450, family 4, subfamily b, polypeptide 1 Metabolism of carcinogens?[44] 0.16
AMF, antimicrobial factor. AA, arachidonic acid.
doi:10.1371/journal.pone.0017996.t001
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Antibiotic treatment protocol
Antibiotic treatment started with three days of amphotericin-B
(Bristol Meyers Squibb, New York City, NY) 0.1 mg/ml,
administered by gavage 12h21 (Figure 2A). From day three, water
flasks were supplemented with ampicillin (Bristol Meyers Squibb,
New York City, NY) 1 g/l and antibiotic concoction consisting of
vancomycin (Abbot, Abbot Park, IL) 5 mg/ml, neomycin
(Invitrogen, Carlsbad, CA) 10 mg/ml, metronidazol (Actavis,
Hafnarfjordur, Iceland) 10 mg/ml, and amphotericin-B (Bristol
Meyers Squibb) 0.1 mg/ml was administered by antibiotic gavage
12h21. Gavage volume of 10 ml/kg body weight was delivered
with a stainless steel tube without prior sedation of the mice. Fresh
antibiotic concoction was mixed every day and ampicillin and
water was renewed every 7th day.
Bacterial cultivation of feces
Day 13 and day 24 of the antibiotic treatment mice were fixed
to defecate directly into a pre-weighted 2 ml capped microtube
(Sarstedt, Nu¨mbrect, Germany) prefilled with 1 ml sterile ice-cold
phosphate-buffered saline (PBS). Tubes with fecal pellets were kept
on ice, weighed and the weight of the pellets calculated (median
46 mg, range 17–120). Fecal pellets were resuspended in the 1 ml
PBS by vortexing and by bashing with a sterile bacteriological
loop. The fecal suspension was then plated on blood agar,
anaerobic blood agar (hemin – vitamin K agar), and yeast agar
(Sabouraud agar) in doubles with 100 ml suspension on each plate.
Blood agar and Sabouraud agar plates were incubated aerobically
at 37uC with 5% CO2 for 72 hours, while anaerobic blood agar
plates were incubated at 37uC in anaerobic conditions for
Figure 5. Antibiotic gavage treatment alters gene expression profile of the colonic epithelium. Gene expression profile of colonic
epithelial cells isolated from mice subjected to 17 days of treatment with vancomycin, neomycin, metronidazol, and amphotericin-B every 12 hours
by gavage with ampicillin ad libitum in drinking water (Treated) compared to mice gavaged with water only (Untreated). All Treated mice exhibited
successful depletion of cultivable intestinal microbiota (,1 cfu/mg feces). (A) Heat-map analysis of significantly (p,0.05) differentially expressed
genes with .two-fold change organized in dendrogram according to Eukledian relation of the differentially expressed genes. Colors indicate
absolute expression of one gene estimated by mean values of the multiple probes detecting each gene on the chip. Each row represent one gene,
each column represent one mouse. (B) Gene ontology map folder enrichment analysis of differentially expressed genes in MetaCore (GeneGo, St
Joseph, MI).
doi:10.1371/journal.pone.0017996.g005
Figure 6. Quantitative PCR validates colonic IEC gene expression profiles of antibiotic treatment in relation to germ-free mice.
Quantitative reverse transcriptase PCR of colonic intestinal epithelial cells (IEC) isolated from mice subjected to 17 days of treatment with vancomycin
(V), neomycin (N), metronidazol (M), and amphotericin-B (Amf-B) every 12 hours by gavage with ampicillin (A) ad libitum in drinking water (VNMAmf-
B+A) compared to mice gavaged with water only (Sham) and from colonic IEC of untreated germ-free mice (GF) and their conventional controls
(Conv). Target gene listed on top of each panel and plotted in relation to the house-keeping gene Hprt. Each symbol represents one mouse,
horizontal bars represent medians. Mann-Whitney analyses between VNMAmf-B+A and Sham, p,0.05 for all genes.
doi:10.1371/journal.pone.0017996.g006
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96 hours. At the end of incubation the numbers of colonies on the
plates were counted and the number of bacteria per mg of feces
calculated. Evaluation of cultivated agar plates was performed by
an experienced bacteriologist (P.G.) The detection limit of the
assay was defined as 1 cfu/mg feces. Only mice successfully
depleted (,1 cfu/mg feces) were included in phenotypic and gene
expression analyses.
As a positive control for the depletion verification assay, and to
enumerate cultivable microbes with the fecal collection procedure,
fecal pellets from untreated mice were collected with the above
described procedure. Serial dilutions made in sterile PBS and suitable
dilutions were plated on selective media for intestinal Gram negative
rods, enterococci, anaerobic Gram negative rods (Bacteroides spp),
Clostridium spp, Lactobacillus spp and Bifidobacterium spp. The aerobic
agar plates were incubated in 37uC with 5% CO2 for 48 hours while
anaerobic agar plates were incubated in 37uC for 48 hours. After
incubation the numbers of colonies on the plates were counted and
the number of bacteria per mg of feces was calculated.
16S rRNA gene quantification
In the same procedure as fecal pellets were collected for
cultivation, the mice were let to defecate directly into a dry 1.5 ml
capped microtube (Sarstedt, Nu¨mbrect, Germany) which was snap
frozen in liquid nitrogen and stored at 270uC until use.
DNA was isolated from bacterial fecal pellets with QIAamp
DNA Stool Mini Kit (Qiagen, Hilden, Germany) and quantified
by spectrophotometry at 260 nm. Degenerate primers for V2 and
V6 region of bacterial 16S genes were as previously de-
scribed[37,38] and primers for mouse genomic DNA was designed
with Primer3 (frodo.wi.mit.edu) (Table 2). All PCR reactions were
carried out with 50 ng of DNA, EvaGreenH (Biotium, Hayward,
California) and Taq2000 in a Stratagene MX3000P with a 15 min
activation step (95uC); then 40 cycles of 30 s denaturation (95uC),
30 s annealing (60uC for 16S-V2 and mpIgR-genomic, 55uC for
16S-V6), and 30 s extension (72uC). The efficiency of each PCR
was determined by dilution series of template. The number of 16S
DNA copies was related to the number of mouse genomic DNA
copies for each sample. Samples with a threshold crossing point
.32 cycles for the genomic PCR were deemed poorly amplifiable
and excluded from analysis.
Organ evaluation
After 17 days of antibiotic treatment mice were anaesthetized with
150 ml HypnormH (fentanyl citrate 0.315 mg/ml and fluanison
Table 2. PCR primers used for amplification of bacterial 16S, mouse genomic DNA, and colonic IEC target genes.
Target Primer name Sequence
16S V2 region 16S-V2-101F[37] AGYGGCGIACGGGTGAGTAA
16S-V2-361R CYIACTGCTGCCTCCCGTAG
16S V6 region 16S-V6-784F[38] AGGATTAGATACCCTGGTA
16S-V6-1061R CRRCACGAGCTGACGAC
Mouse pIgR genomic region mpIgRgenomic.for TTTGCTCCTGGGCCTCCAAGTT
mpIgRgenomic.rev AGCCCGTGACTGCCACAAATCA
Angiogenin, ribonuclease A family, member 4 Ang4.for TCTCCAGGAGCACACAGCTA
Ang4.rev AAGGACATGGGCTCATTGTC
Phospholipase A2, group IIA Pla2g2a.for CTGTTGCTACAAGAGCCTGG
Pla2g2a.rev TTTTCTTGTTCCGGGCGAAA
Resistin like beta Retnlb.for AGGATCAAGGAAGCTCTCAGTC
Retnlb.rev ATTTCCATTCCGGATATCCCA
Phospholipase A2, group IVC Pla2g4c.for AAGGCTCTCAGACTGTGGAG
Pla2g4c.rev GCCCACAGTACCCTGAAAAC
Regenerating islet-derived 3 gamma Reg3g.for ACATCAACTGGGAGACGAATC
Reg3g.rev TTTGGGATCTTGCTTGTGGCTA
Regenerating islet-derived 3 beta Reg3b.for CCTTAGACCGTGCTTTCTGTG
Reg3b.rev GTCCATGATGCTCTTCAAGACA
Gasdermin C2 Gsdmc2.for GGACCTGGAGGCTAACTTGA
Gsdmc2.rev CCTTTCCATCCGGCAAAACT
Caspase 14 Casp14.for ATCTCAGGAGAAGCTTGGGG
Casp14.rev TCTGGCTTTCAGCACCTTTG
Cytochrome P450, family 4, subfamily b, polypeptide 1 Cyp4b1.for TGATCCTGATGGTAACCGTCC
Cyp4b1.rev CATAGGGGAACTGTTCGGTC
Hypoxanthine guanine phosphoribosyl transferase HPRT.for TGATCAGTCAACGGGGGACA
HPRT.rev TTCGAGAGGTCCTTTTCACCA
Beta 2 microglobulin B2m.for TGACCGGCCTGTATGCTATC
B2m.rev GCAGTTCAGTATGTTCGGCT
Target region, name and sequence of primers used in this study. The matching forward and reverse primers targeted to mouse cDNA lie in separate exons of each gene.
doi:10.1371/journal.pone.0017996.t002
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10 mg/ml, VetaPharma Ltd, Leeds, UK) and midazolam (5 mg/ml,
B. BraunMelsungen AG, Melsungen, Germany) subcutaneously and
sacrificed by cardiac puncture. Abdominal organs were swiftly
dissected and evaluated by a technician blinded to the treatment of
the individual animal. Macroscopically visible Peyer’s patches along
the entire length of the small intestines from the ventricle to the
ileocecal junction were counted. Cecum was gently put on its side
along a ruler, digitally photographed and with the software
analySISpro (Olympus Europa, Hamburg, Germany) the longitudi-
nal cross section area of the cecum was calculated. The intact spleen
was excised, abdominal fat gently removed, and the spleen was put in
10% formalin for 24 h, and then removed from the formalin, excess
liquid wiped off with a filter paper, and the spleen was weighted.
Immunohistochemistry
Colons of sacrificed mice were swiftly dissected and flushed with
2610 ml of ice cold PBS. A 1.5 cm piece of the middle colon was
cut off and instantly fixed in 10% formalin for 24 h at 4uC before
being automatically processed (TP 1050, Leica Microsystems,
Wetzlar, Germany) and embedded in paraffin. Sections were cut
at 4 mm thickness, deparaffinized and incubated 20 minutes in
preheated 0.05% citraconic anhydride pH 7.4 at 98uC. After
cooling to room temperature the sections were incubated 18 h
with rabbit anti-Ki67 (Abcam, Cambridge, UK) or isotype control
(rabbit anti-hemocyanin, Sigma, St. Louis, MR) at 4uC. After
washing with PBS (pH 7.4) sections were incubated 90 minutes
with Alexa Fluor 488 conjugated goat anti-rabbit IgG (Molecular
Probes, Eugene, OR) at room temperature. After another washing
in PBS sections were stained with Hoechst dye before being rinsed
in water and mounted with PVA under cover slips.
Slides were evaluated by one examiner (D.H.R) a blinded
fashion with the help of microscope (Eclipse E800, Nikon, Tokyo,
Japan) fitted with a digital camera and imaging software
(AnalySISpro 3.2, Olympus Soft Imaging System GmbH,
Mu¨nster, Germany). Enumeration of Ki67+ cells were performed
by calculating the mean number of positive cells in 5–8 crypts in
each transverse section ensuring crypts were cut to display the full
crypt heights.
Isolation of colonic IECs and microarray
After 17 days of antibiotic treatment mice were anaesthetized
with 150 ml HypnormH (fentanyl citrate 0.315 mg/ml and
fluanison 10 mg/ml, VetaPharma Ltd) and midazolam (5 mg/
ml, B. Braun Meslungen AG) subcutaneously and bled to death by
cardiac puncture. Colon was swiftly excised and flushed with 26
10 ml ice cold PBS (w/o Mg2+ and Ca2+) and kept moist.
Mesenteric and adipose tissue was removed from the colon which
was subsequently opened longitudinally, then cut transversally in
5 cm long pieces and incubated 25 min in 25 ml 20 mM EDTA
(Sigma-Aldrich, St. Louis, MO) at room temperature on a shaker
before being vigorously hand shaken for 5 minutes. The colonic
IECs were harvested in a fresh tube, washed twice in ice cold PBS,
resuspended in TRI ReagentH (Ambion Applied Biosystems,
Foster City, CA), and stored at 270uC until RNA isolation
according to manufacturer’s instructions.
Gene expression profiling was performed at the Microarray
Core Facility at The Norwegian Radium Hospital (Oslo, Norway).
Total RNA corresponding to samples of 5 microbiota depleted
mice and 6 control mice were labeled and hybridized to Illumina’s
MouseWG-6 v2.0 Expression BeadChips (Illumina, Inc., San
Diego, CA) according to manufacturer’s protocol. Normalization
and statistical analysis of gene expression was performed in R
(www.r-project.org) using Bioconductor packages and differentially
expressed genes were identified using moderated t-statistics with
an adjusted p-value ,0.05. Differentially expressed genes were
further analyzed in MetaCore (GeneGo, St Joseph, MI) to identify
functional enrichment. Process and pathways were selected based
on a p-value , 0.05. The complete gene expression dataset can be
viewed in the Gene Expression Omnibus (GEO) repository
accession number GSE22648 (www.ncbi.nlm.nih.gov/geo/que-
ry/acc.cgi?acc =GSE22648). Data submitted complied with
MIAME standards.
Quantitative RT-PCR
Epithelial cells and mRNA were isolated as described above.
cDNA was synthesized with SuperscriptTM III Reverse transcrip-
tase (Invitrogen) and 20 pmol/ml oligo(dT) according to manu-
facturer’s protocol. The PCR primers were selected with the ‘‘Pick
PCR primer’’ tool available from NCBI (http://www.ncbi.nlm.
nih.gov) making sure each primer pair was separated by an intron
on genomic DNA. The optimal Mg++ concentration was
determined empirically for each primer pair and PCR performed
with EvaGreenH (Biotium, Hayward, California) and Taq2000 in
a Stratagene MX3000P with a 15 min activation step (95uC); then
35 cycles of 30 s denaturation (95uC), 30 s annealing (60u), and
30 s extension (72uC). The median value of triplets were used to
calculate relative expression of each gene according to the DDCt
method[39]. Normalization to the housekeeping genes hprt or b2-
microglobulin gave similar results.
Statistics
Where appropriate, statistical differences were calculated by
Mann-Whitney two- tailed test using the software Prism5
(GraphPad Softvare Inc., La Jolla, CA).
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